Source: http://www.google.com/patents/USRE42461?dq=7,173,247
Timestamp: 2015-07-03 18:04:33
Document Index: 405935827

Matched Legal Cases: ['art 1', 'art 2', 'art 1', 'art 2', 'art 3', 'art 4', 'art 1', 'art 2', 'art 1', 'art 2', 'art 3', 'art 1', 'art 2', 'art 1', 'art 2', 'art 3', 'art 1', 'art 2', 'art 3', 'art 4', 'art 1', 'art 2', 'art 3', 'art 4', 'art 5', 'art 6', 'art 3', 'art 1']

Patent USRE42461 - Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsHydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6,...http://www.google.com/patents/USRE42461?utm_source=gb-gplus-sharePatent USRE42461 - Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agentsAdvanced Patent SearchPublication numberUSRE42461 E1Publication typeGrantApplication numberUS 12/797,341PCT numberPCT/US1994/010099Publication dateJun 14, 2011Filing dateSep 14, 1994Priority dateSep 21, 1993Also published asCA2172149C, CN1050830C, CN1131416A, DE10399001I1, DE10399001I2, DE69418613D1, DE69418613T2, DE122004000026I1, DE122004000026I2, EP0720599A1, EP0720599B1, US5631365, US5767115, USRE37721, WO1995008532A1Publication number12797341, 797341, PCT/1994/10099, PCT/US/1994/010099, PCT/US/1994/10099, PCT/US/94/010099, PCT/US/94/10099, PCT/US1994/010099, PCT/US1994/10099, PCT/US1994010099, PCT/US199410099, PCT/US94/010099, PCT/US94/10099, PCT/US94010099, PCT/US9410099, US RE42461 E1, US RE42461E1, US-E1-RE42461, USRE42461 E1, USRE42461E1InventorsStuart B. Rosenblum, Sundeep Dugar, Duane A. Burnett, John W. Clader, Brian A. McKittrickOriginal AssigneeSchering CorporationExport CitationBiBTeX, EndNote, RefManPatent Citations (99), Non-Patent Citations (515), Referenced by (1), Classifications (13), Legal Events (1) External Links: USPTO, USPTO Assignment, EspacenetHydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4144232Nov 30, 1977Mar 13, 1979Eli Lilly And CompanySubstituted azetidin-2-one antibioticsUS4375475Feb 11, 1981Mar 1, 1983Merck & Co., Inc.Substituted pyranone inhibitors of cholesterol synthesisUS4443372Jun 23, 1982Apr 17, 1984Chevron Research Company1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulatorsUS4479900Apr 29, 1983Oct 30, 1984Chevron Research Company1-Carbalkoxyalkyl-3-aryloxy-4-(2'-carboxyphenyl)-azetidin-2-onesUS4500456Dec 27, 1982Feb 19, 1985Eli Lilly And CompanyPreparation of 4-fluoroazetidinones using FClO3US4576749Apr 13, 1984Mar 18, 1986E. R. Squibb & Sons, Inc.3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinonesUS4576753Jul 9, 1984Mar 18, 1986Fujisawa Pharmaceutical Co., Ltd.Azetidinone compounds and processes for preparation thereofUS4595532Apr 1, 1985Jun 17, 1986University Of Notre Dame Du LacN-(substituted-methyl)-azetidin-2-onesUS4620867Sep 28, 1984Nov 4, 1986Chevron Research Company1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicidesUS4633017Oct 24, 1985Dec 30, 1986E. R. Squibb & Sons, Inc.N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinonesUS4659716Mar 12, 1986Apr 21, 1987Schering CorporationAntihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridinesUS4675399Oct 3, 1985Jun 23, 1987Notre Dame UniversityCyclization process for β-lactamsUS4680391Apr 10, 1985Jul 14, 1987Merck & Co., Inc.Substituted azetidinones as anti-inflammatory and antidegenerative agentsUS4759923Jun 25, 1987Jul 26, 1988Hercules IncorporatedProcess for lowering serum cholesterol using poly(diallylmethylamine) derivativesUS4784734Jul 9, 1987Nov 15, 1988Otsuka Kagaku Yakuhin Kabushiki KaishaAzetidinone derivatives and process for the preparation of the sameUS4794108Sep 14, 1984Dec 27, 1988Takeda Chemical Industries, Ltd.1-carboxymethoxy acetidinones and their productionUS4803266Oct 5, 1987Feb 7, 1989Taisho Pharmaceutical Co., Ltd.3-Oxoalkylidene-2-azetidinone derivativesUS4806564May 26, 1987Feb 21, 1989Merck & Co., Inc.Antihypercholesterolemic beta-lactonesUS4816477May 26, 1987Mar 28, 1989Merck & Co., Inc.Antihypercholesterolemic β-lactonesUS4834846Dec 7, 1987May 30, 1989Merck & Co., Inc.Process for deblocking N-substituted β-lactamsUS4847271Mar 4, 1987Jul 11, 1989Merck & Co., Inc.Antihypercholesterolemic β-lactonesUS4876365Dec 5, 1988Oct 24, 1989Schering CorporationIntermediate compounds for preparing penems and carbapenemsUS4983597Aug 31, 1989Jan 8, 1991Merck & Co., Inc.Beta-lactams as anticholesterolemic agentsUS5030628Dec 19, 1989Jul 9, 1991ScientifiqueN-aryl-azetidinones, their preparation process and their use as elastase inhibitorsUS5099034Jun 27, 1990Mar 24, 1992Shionogi & Co., Ltd.Phospholipase a2 inhibitorUS5120729Jun 20, 1990Jun 9, 1992Merck & Co., Inc.Beta-lactams as antihypercholesterolemicsUS5124337May 20, 1991Jun 23, 1992Schering CorporationN-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferaseUS5159025Jun 12, 1989Oct 27, 1992Idemitsu Petrochemical Co., Ltd.Styrene-based copolymer and process for production thereofUS5229381Sep 20, 1991Jul 20, 1993Merck & Co., Inc.Substituted azetidinones as anti-inflammatory and antidegenerative agentsUS5229510Jan 3, 1992Jul 20, 1993Merck & Co., Inc.β-lactams useful in determining the amount of elastase in a clinical sampleUS5238950Dec 17, 1991Aug 24, 1993Schering CorporationInhibitors of platelet-derived growth factorUS5306817Oct 19, 1992Apr 26, 1994Schering CorporationProcess for the stereospecific synthesis of azetidinonesUS5348953Dec 17, 1992Sep 20, 1994Merck & Co., Inc.Substituted azetidinones as anti-inflammatory and antidegenerative agentsUS5350868Feb 19, 1993Sep 27, 1994Ube Industries, Ltd.ω-hydroxy-(ω-3)-ketonitrile and method for preparing ω-hydroxyaliphatic acidUS5412092Dec 13, 1993May 2, 1995Bristol-Myers Squibb CompanyN-substituted 2-azetidinonesUS5550229Jun 21, 1994Aug 27, 1996Tanabe Seiyaku Co., Ltd.Alkylation process for preparing azetidinone compound and starting compound thereforUS5576470Aug 29, 1994Nov 19, 1996Henkel CorporationPolyol esters of ether carboxylic acids and fiber finishing methodsUS5595997Dec 30, 1994Jan 21, 1997Sepracor Inc.Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadineUS5624920Nov 18, 1994Apr 29, 1997Schering CorporationSulfur-substituted azetidinone compounds useful as hypocholesterolemic agentsUS5631365Jun 9, 1994May 20, 1997Schering CorporationHydroxy-substituted azetidinone compounds useful as hypocholesterolemic agentsUS5633246Jun 5, 1995May 27, 1997Schering CorporationSulfur-substituted azetidinone compounds useful as hypocholesterolemic agentsUS5661145Dec 21, 1993Aug 26, 1997Schering CorporationCombination of a cholesterol biosynthesis inhibitor and a β-lactam cholesterol absorption inhibitorUS5688785May 25, 1995Nov 18, 1997Schering CorporationSubstituted azetidinone compounds useful as hypocholesterolemic agentsUS5688787Jan 19, 1996Nov 18, 1997Schering CorporationSubstituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereofUS5688990May 18, 1995Nov 18, 1997Shankar; Bandarpalle B.Substituted azetidinone compounds useful as hypocholesterolemic agentsUS5698548May 25, 1995Dec 16, 1997Schering CorporationSpirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agentsUS5728827Jul 1, 1994Mar 17, 1998Schering CorporationProcess for the synthesis of azetidinonesUS5739321May 31, 1996Apr 14, 1998Schering Corporation3-hydroxy γ-lactone based enantionselective synthesis of azetidinonesUS5744467Jan 8, 1997Apr 28, 1998Schering CorporationSulfur-substituted azetidinone compounds useful as hypocholesterolemic agentsUS5767115Mar 18, 1996Jun 16, 1998Schering-Plough CorporationHydroxy-substituted azetidinone compounds useful as hypocholesterolemic agentsUS5767126May 7, 1992Jun 16, 1998Marchbanks; Roger MichaelAlzheimer's disease treatment with tacrine metabolitesUS5817806Mar 23, 1995Oct 6, 1998Glaxo Wellcome SpaProcess for the preparation of cyclohexyl-azetidinonesUS5846966Oct 14, 1997Dec 8, 1998Schering CorporationCombinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase InhibitorsUS5847115Nov 1, 1996Dec 8, 1998Tanabe Seiyaku Co., Ltd.Azetidinone compound and process for preparation thereofUS5856473Oct 31, 1996Jan 5, 1999Schering CorporationProcess for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinoneUS5925668Jan 20, 1998Jul 20, 1999Asta Medica AktiengesellschaftThioctic metabolites and methods of use thereofUS6372756Feb 19, 1999Apr 16, 2002Avmax, Inc.Epimorphian compound and its useUS6455572Apr 4, 2001Sep 24, 2002Pfizer Inc.Estrogen agonist/antagonist metabolitesUS6465490Jul 13, 2000Oct 15, 2002Aventis Pharmaceuticals Inc.Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]esterUS6982251Jun 11, 2002Jan 3, 2006Schering CorporationSubstituted 2-azetidinones useful as hypocholesterolemic agentsUSRE36481Nov 4, 1998Jan 4, 2000Merck & Co., Inc.HMG-CoA reductase inhibitorsCA1063108A1Jul 4, 1975Sep 25, 1979Fujisawa, Pharmaceutical Co.Azetidinone derivatives and process for preparation thereofCA1173837A1Mar 4, 1982Sep 4, 1984Theodore Goodson, Jr.4-fluoroazetidinonesCA1213596A1Apr 10, 1984Nov 4, 1986Tatao Luo1-alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)- phenyl-azet-2-ones as plant growth regulatorsCA1253146A1Sep 14, 1984Apr 25, 1989William A. SlusarchykAzetidinonesCA1262357A1Jul 17, 1985Oct 17, 1989Richard H. MuellerN-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinonesCA1267415A1Jan 26, 1984Apr 3, 1990University Of Notre Dame Du LacN-(substituted-methyl)-azetidin-2-onesCA1268780A2Apr 3, 1989May 8, 1990Richard H. MuellerN-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinonesCA1286304CApr 4, 1986Jul 16, 1991Peter L. BarkerSubstituted azetidinones as anti-inflammatory and antidegenerative agentsCA1331755CMar 21, 1984Aug 30, 1994Marvin Joseph MillerProcess for producing .beta.-lactam compoundsCA2004355A1Dec 1, 1989Jun 5, 1990Michael P. KirkupProcess for intermediate compounds for preparing penems and carbapenemsCA2024267A1Aug 29, 1990Mar 1, 1991Shu S. YangBeta-lactams as anticholesterolemic agentsCA2052973A1Oct 8, 1991Apr 16, 1992Conrad P. DornSubstituted azetidinones as anti-inflammatory and antidegenerative agentsCA2072215A1Jun 24, 1992Dec 26, 1992Paul E. FinkeNew substituted azetidinones as anti-inflammatory and antidegenerative agentsCA2114007A1Jul 21, 1992Feb 4, 1993Schering CorpSubstituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereofCA2152351A1Dec 21, 1993Jul 7, 1994Schering CorpCombination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitorCA2154257A1Jan 19, 1994Aug 4, 1994Schering CorpSpirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agentsCA2172149CSep 14, 1994Nov 28, 2000Stuart B. RosenblumHydroxy-substituted azetidinone compounds useful as hypocholesterolemic agentsDE2046823A1Sep 23, 1970Mar 30, 1972 Title not availableEP0199630A1Apr 8, 1986Oct 29, 1986Merck &amp; Co., Inc.Substituted azetidinones, pharmaceutical compositions containing them, and their use for the manufacture of anti-inflammatory and antidegenerative medicamentsEP0264231A1Oct 9, 1987Apr 20, 1988Taisho Pharmaceutical Co. LtdAzetidinone derivativesEP0333268A1Mar 10, 1989Sep 20, 1989Merck &amp; Co., Inc.Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinoneEP0337549A1Apr 6, 1989Oct 18, 1989Merck &amp; Co., Inc.New substituted azetidinones as anti-inflammatory and antidegenerative agentsEP0365364A2Oct 20, 1989Apr 25, 1990Taisho Pharmaceutical Co. Ltd2-Azetidinone derivativesEP0401705A2Jun 1, 1990Dec 12, 1990E.R. Squibb &amp; Sons, Inc.Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic diseaseEP0415487A2Aug 24, 1990Mar 6, 1991Merck &amp; Co., Inc.Beta-lactams as anticholesterolemic agentsEP0462667A2Jun 14, 1991Dec 27, 1991Merck &amp; Co., Inc.Beta-lactams as antihypercholesterolemicsEP0481671A1Oct 9, 1991Apr 22, 1992Merck &amp; Co., Inc.New substituted azetidinones as anti-inflammatory and antidegenerative agentsEP0508425A1Apr 9, 1992Oct 14, 1992Schering CorporationBicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferaseEP0524595A1Jul 21, 1992Jan 27, 1993Schering CorporationSubstituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereofEP0720599A1Sep 14, 1994Jul 10, 1996Schering CorporationHydroxy-substituted azetidinone compounds useful as hypocholesterolemic agentsJPH08505141A Title not availableWO1987004429A1Jan 12, 1987Jul 30, 1987Upjohn CoAntimicrobial n-acyl-2-azetidinonesWO1993002048A1Jul 21, 1992Feb 4, 1993Schering CorpSubstituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereofWO1994006784A1Sep 21, 1993Mar 31, 1994Schering Corp1,2-disubstituted ethyl amides as inhibitors of acatWO1994014433A1Dec 21, 1993Jul 7, 1994Schering CorpCOMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A β-LACTAM CHOLESTEROL ABSORPTION INHIBITORWO1994017036A1Jan 22, 1993Aug 4, 1994Inst Nat Sante Rech MedS-lipophilic aliphatic carbonyl [n-mercaptoacyl-(amino acid or peptide)] compounds as antihypertensive agentsWO1994017038A1Jan 19, 1994Aug 4, 1994Schering CorpSpirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agentsWO1994019351A1Feb 24, 1994Sep 1, 1994Schering Corp2-benzyl-polycyclic guanine derivatives and process for preparing themNon-Patent CitationsReference1"Heart disease" Statistics http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.html#heartdiesease � 2010.2Abel et al., Cortisol Metabolism by Human Liver in vitro-I Metabolite identification and Inter-Individual Variability, J. Steroid. Biochem. Molec. Biol. 43(7):713-719 (1992).3Abel et al., Cortisol Metabolism by Human Liver in vitro-IV. Metabolism of 9 alpha-fluorocortisol by Human Liver Microsomes and Cytosol., J. Steroid. Biochem. Molec. Biol. 46(6):833-839 (1993).4Abel et al., Cortisol Metabolism by Human Liver in vitro-IV. Metabolism of 9 α-fluorocortisol by Human Liver Microsomes and Cytosol., J. Steroid. Biochem. Molec. Biol. 46(6):833-839 (1993).5Affidavit of A. Louise McLean, dated Apr. 9, 2009, Federal Court of Canada (Court File No. T-1610-08).6Affidavit of Antonio M. Gotta Jr., M.D., D.Phil. re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jul. 6, 2009, Federal Court of Canada (Court File No. T-1610-08).7Affidavit of Dr. John Clader (Inventor) re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jun. 26, 2009, Federal Court of Canada (Court File No. T-1610-08).8Affidavit of Gary Thiessen re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SSR/06-242; SOR/2008-211, dated Jun. 30, 2009, Federal Court of Canada (Court File No. T-1610-08).9Affidavit of Glenn Ikeda, dated Apr. 13, 2009, Federal Court of Canada (Court File No. T-1610-08).10Affidavit of John D. Sutherland, dated Apr. 6, 2009, Federal Court of Canada (Court File No. T-1610-08).11Affidavit of Leslie Z. Benet re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 2, 2009, Federal Court of Canada (Court File No. T-1610-08).12Affidavit of Mark Wentland re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 3, 2009, Federal Court of Canada (Court File No. T-1610-08).13Affidavit of Neal Castagnoli, Ph.D. re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations. SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jul. 2, 2009, Federal Court of Canada (Court File No. T-1610-08).14Affidavit of Sonia Atwell re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SSR/98-66; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 3, 2009, Federal Court of Canada (Court File No. T-1610-08).15Ajmera et al., Synthesis and Biological Activity of 5-Fluoro-2',3'-dideoxy-3'-Fluorouridine and Its 5'-Phosphate, J. Med. Chem. 27(1):11-14 (1984).16Ajmera et al., Synthesis and Biological Activity of 5-Fluoro-2′,3′-dideoxy-3′-Fluorouridine and Its 5′-Phosphate, J. Med. Chem. 27(1):11-14 (1984).17Allain et al., Enzymatic Determination of Total Serum Cholesterol, Clinical Chemical 20:470-475 (1974).18Altmann et al., Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption, Science 303:1201-1204 (2004).19Altschul et al., Influence of Nicotinic Acid on Serum Cholesterol in Man, Arch Biochem, 54(2):558-559 (1955).20Amended Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: May 3, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).21Amended Answer to Complaint, Separate Defenses, Amended Counterclaim and Jury Demand against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Mar. 2, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).22American Heritage Dictionary of the English language, 2nd College ed., Houghton Mifflin Co.-"appy as remedy" (1985).23American Heritage Dictionary of the English language, 2nd College ed., Houghton Mifflin Co.—"appy as remedy" (1985).24Angelin et al., Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition, Eur. J. Clin. Invest. 16:391-396 (1986).25Anitschkow and Chalatow, On Experimental Cholesterin Steatosis and Its Significance in the Origin of Some Pathological Processes, Arteriosclerosis 3(2):178-182 (1983).26Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).27Answer to Complaint with Jury Demand , Separate Defenses, Counterclaim against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Jul. 28, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-03085-JLL-CCC).28Answer to Complaint, Counterclaim against all plaintiffs by Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Corporate Disclosure Statement)(Walsh, Liza) (Entered: May 23, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).29Answer to Complaint, Separate Defenses, Counterclaim against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Feb. 12, 2010), U.S. District Court for ihe District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).30Answer to Counterclaim Amended Counterclaim of Glenmark Pharmaceuticals Ltd. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certification of Service)(Halper, Jason) (Entered: Apr. 9, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).31Answer to Counterclaim Amended Counterclaim of Glenmark Pharmaceuticals, Inc. USA by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certification of Service)(Halper, Jason) (Entered: Apr. 9, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).32Answer to Counterclaim by MSP Singapore Company LLC, Schering Corporation.(Halper, Jason) (Entered: Apr. 7, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).33Answer to Counterclaim of Glenmark Pharmaceuticals, Inc. USA. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Jul. 3, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).34Answer to Counterclaim of Glenmark Pharmaceuticals, Ltd. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Jul. 3, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).35Arnerican Heart Association/American Stroke Association Report Dec. 2009, "Facts: Breaking Our Hearts: Still America's No. 1 Killer," formerly accessible at http://www.americanheart.org/presenter.jhdml?identifierequal3049018 (cited as document C32 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).36Augelli-Szafran et al., Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel alpha-ketoamides as hypocholesterolemic agents, J. Med. Chem. 36(20):2943-2949 (1993).37Augelli-Szafran et al., Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel α-ketoamides as hypocholesterolemic agents, J. Med. Chem. 36(20):2943-2949 (1993).38Austel and Kutter, Quant. Struct. Activity Relationships of Drugs, John G. Toplissm (ed.), Academic Press, pp. 437-496 (1983).39B. Ram et al., 1990, "Potential hypolipidemic agents:Part V†-Synthesis biological activity of new ethyl 4-(2-oxoazetidin-4-yl)phenoxyalkanoates‡" Indian Journal of Chemistry 29B:1134-1137.40Bannai et al., Synthesis of Chemically Stable Prostacyclin Analogs, Tetrahedron 39(22):3807-3819 (1983).41Barnard et al., The Effect of Fluorine Substitution on the Physicochemical Properties and the Analgesic Activity of Paracetamol, J. Pharm. Pharmacol. 45(8):736-744 (1993).42Bass et al., Effect of Ring Fluorination of Epinephrine on Its Cardiovascular Adrenoceptor Activities, Eur. J. Pharmacol. 187(1):87-95 (1990).43Baxter, A., 1992, "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo," The Journal of Biological Chemistry 267:11705-11708.44Baxter, Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in vivo, Journal of Biological Chemistry 267:11705-11708 (1992).45Bergstrom and Shum, Synthesis and Characterization of a New Fluorine Substituted Nonionic Dinucleoside Phosphonate Analogue, P-Deoxy-P-(difluoromethyl)thymidyly1(3′-> 5′)thymidine, J. Org. Chem. 53:3953-3958 (1988).46Bergstrom and Shum, Synthesis and Characterization of a New Fluorine Substituted Nonionic Dinucleoside Phosphonate Analogue, P-Deoxy-P-(difluoromethyl)thymidyly1(3'-> 5')thymidine, J. Org. Chem. 53:3953-3958 (1988).47Bergstrom et al., 3',3'-Difluoro-3'-Deoxythymidine:Comparison of Anti-HIV Activity to 3'-Fluoro-3'-Deoxythymidine, J. Med. Chem. 35(18):3369-3372 (1992).48Bergstrom et al., 3′,3′-Difluoro-3′-Deoxythymidine:Comparison of Anti-HIV Activity to 3′-Fluoro-3′-Deoxythymidine, J. Med. Chem. 35(18):3369-3372 (1992).49Bergstrom et al., Fluorine Substituted Analogs of Nucleosides and Nucleotides, Nucleos, Nucleot. 6(1 & 2):53-63 (1987).50Bey et al., Further Studies on the Inhibition of Monoamine Synthesis by Monofluoromethyldopa, Br. J. Pharmacol, 70(4):571-576(1980).51Black et al., Modulation of Carcinogenicity in 1,2, 3, 4-Tetrahydro-7,12-Dimethylbenz[a] Anthracene (THDMBA) by Fluorine Substitution: Crystal Structures of the 5- and 6- Fluoro Regioisomers, Carcinogenesis 13(8):1337-1343 (1992).52Blackburn et al., Isopolar vs isosteric Phosphonate Analogues of Nucleotides, Nucleos. Nucleot. 4(1 & 2):165-167 (1985).53Blackburn, Overview: The Seven Countries Study in Brief, http://www.epi.umn.edu/research/7countries/overview/shtm, downloaded on Aug. 10, 2010.54Blankenhorn and Hodis, Treating serum lipid abnormalities in high-priority patients, Postgrad. Med., 89(1):81-96 (1991).55Boersma et al., Role of Cytochromes P-450 and Flavin-Containing Monooxygenase in the Biotransformation of 4-Fluoro-N-Methylaniline, Drug Metab. Dispos. 21(2):218-230 (1993) (Abstract only).56Boersma et al., Role of Cytochromes P-450 and Flavin-Containing Monooxygenase in the Biotransformation of 4-Fluoro-N-Methylaniline, Drug Metab. Dispos. 21(2):218-230 (1993) (full copy) (cited in abstract form as document C52 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).57Braun and Galle, A simple stereoselective synthesis of cholestrol absorption inhibitor (--)- SCH 48461, Synthesis 7:819-820 (1996).58Bravo et al., Synthesis and Pharmacological Evaluation of Enantiomerically Pure 4-Deoxy-4-Fluoromuscarines, J. Med. Chem. 35(17):3102-3110 (1992).59Brief in Opposition re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Rule 56.1 Responsive Statement of Material Facts, # 2 Suh Declaration, # 3 Suh Declaration Exhibits (Redacted), # 4 Proposed Order, # 5 Certification of Service)(Halper, Jason) (Entered: Jul. 22, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).60Brief in Opposition re Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13 filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Proposed Order, # 2 Certification of Service)(Walsh, Liza) (Entered: May 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).61Brief in Opposition re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Local Rule 56.1 Statement of Facts, # 2 Proposed Order, # 3 Certification of Service)(Halper, Jason) (Entered: Aug. 5, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).62Brief in Opposition to Defendants' Opening Markman Brief filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Supplemental Krause Declaration, # 2 Supp. Krause Declaration, Exs. R-V, # 3 Supp. Krause Declaration, Exs. W-Y, # 4 Certification of Service)(Halper, Jason) (Entered: Feb. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).63Brief in Response to Defendant's Opening Markman Brief filed by MSP Singapore Company LLC, Schering Corporation (Redacted) (Attachments: # 1 Supplemental Declaration of James Suh, # 2 Supp. Suh Declaration, Exhibit 38, # 3 Supp. Suh Declaration, Exhibit 39, # 4 Supp. Suh Declaration, Exhibit 40, # 5 Supp. Suh Declaration, Exhibit 41 (Redacted)), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).64Brief In Response To Plaintiffs' Proposed Claim Interpretations filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Certification of Service)(Walsh, Liza) (Entered: Feb. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).65Brief—Mylan's Responsive Claim Construction Brief filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 40 to the Declaration (Supplemental) of Srilakshmi M. Ravi), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).66Brockman et al., Metabolism and Chemotherapeutic Activity of 9-beta-D-Arabinofuranosyl-2-Fluoroadenine against Murine Leukemia L1210 and Evidence for Its Phosphorylation by Deoxycytidine Kinase, Cancer Res. 40(10):3610-3615 (1980).67Brockman et al., Metabolism and Chemotherapeutic Activity of 9-β-D-Arabinofuranosyl-2-Fluoroadenine against Murine Leukemia L1210 and Evidence for Its Phosphorylation by Deoxycytidine Kinase, Cancer Res. 40(10):3610-3615 (1980).68Brodbeck et al., Fluorinated Aldehydes and Ketones Acting as Quasi-Substrate Inhibitors of Acetylcholinesterase, Biochim. Biophys. Acta. 567(2):357-369 (1979).69Brooks and Wiley, Evolution as Entropy. Towards a Unified Theory of Biology, D.L. Hull (editor) Second Edition (University of Chicago Press), Table of Contents (1968).70Brown and Bowden, New Twists on an Old Theme, Chem. Ind. 5:143-147 (1993).71Brown, Review of Clinical Studies of Fenofibrate in Combination with Currently Approved Lipid-Lowering Drugs, Cardiology 76(1):45-54 (1989).72Buffa and Peters, The in vivo Formation of Citrate Induced by Fluoroacetate and Its Significance, J. Physiol. 110(3-4):488-500 (1950).73Bugrim, "Early Prediction of Drug Metabolism and Toxicity: Systems Biology Approach and Modeling," Drug Discovery Today 9(3):127-135 (2004).74Buhler et al. Metabolism and Tumorigenicity of 7-, 8-,9-, and 10-Fluorobenzo(a) Pyrenes, Cancer Res. 42(11):4779-4783 (1982).75Burger, Progress in Drug Research. Fortschritte der Arneimittelforschung Progres des rescherches pharmaceutiques, Prog. Drug. Res. 37:287-371 (1991).76Burnett and Davis, "Chapter 6. Recent Advances in the Science and Treatment of Atherosclerosis," Annual Reports In Med. Chem., vol. 36, pp. 57-66 (Greenlee, Ed.), Academic Press (2001).77Burnett at al., 2-Azetidinones as Inhibitors of Cholesterol Absorption, J. Med. Chem. 37(12):1733-1736 (1994).78Burnett et al., Synthesis of Iodinated Biochemical Tools Related to the 2-Azetidinone Class of Cholesterol Absorption Inhibitors, Biorg. & Med. Chem. Letters 12:311-314 (2002).79Burnett, Asymmetric synthesis and absolute stereochemistry of cholesterol absorption inhibitor, SCH 48461, Tet. Letters 35(40):7339-7342 (1994).80Burnett, beta-Lactam Cholesterol absorption inhibitors, Curr. Med. Chem. 11:1873-1887 (2004).81Burnett, β-Lactam Cholesterol absorption inhibitors, Curr. Med. Chem. 11:1873-1887 (2004).82Burrier et al., Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster, Biochemical Pharmacology 47:1545-1551 (1994).83Burrier et al., The Effect of Acyl CoA: Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine. J. Pharmacol. Exp. Ther. 372(1): 156-163 (1995).84Burrier et al., The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine, The Journal of Pharmacology and Experimental Therapeutics 272:156-163 (1994).85Burrier, R.E. et al., 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", Biochemical Pharmacology 47:1545-1551.86Burrier, R.E. et al., 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", The Journal of Pharmacology and Experimental Therapeutics 272:156-163.87Bush and Mahesh Metabolism of 11-Oxygenated Steroids. 2. 2-Methyl Steroids, Biochem. J. 71(4):718-742 (1959).88Bush and Mahesh, Metabolism of 11-Oxygenated Steroids. 3. Some 1-Dehydro and 9 alpha-fluoro Steroids, Biochem. J. 93(2):236-255 (1964).89Bush and Mahesh, Metabolism of 11-Oxygenated Steroids. 3. Some 1-Dehydro and 9 α-fluoro Steroids, Biochem. J. 93(2):236-255 (1964).90Butler and Gray, The Metabolism of Betamethasone, J. Endocrinol. 46(3):379-390 (1970).91C. Allain et al., 1974, "Enzymatic Determination of Total Serum Cholesterol" Clinical Chemical, 20:470-475.92Campbell et al., beta-Lactamase Activity of Purified and Partially Characterized Human Renal Dipeptidase, J. Biol. Chem. 259(23):14586-14590 (1984).93Campbell et al., β-Lactamase Activity of Purified and Partially Characterized Human Renal Dipeptidase, J. Biol. Chem. 259(23):14586-14590 (1984).94Carpenter et al., Pharmacokinetics of Inhaled Anesthetics in Humans: Measurements During and After the Simultaneous Administration of Enflurane, Halothane, Isoflurane, Methoxyflurane, and Nitrous Oxide, Anesth. Analg. 65(6):575-582 (1986).95Carrell et al., Fluorocitrate Inhibition of Aconitase: Relative Configuration of Inhibitory Isomer by X-Ray Crystallography Science 170(965):1412-1414 (1970).96Cates, Calculation of drug solubilities by pharmacy students, Am. J. Pharm. Ed., 45:11-13 (1981).97Certification in Opposition re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) Declaration of James Suh filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exibits 1-4, # 2 Exhibits 5-16, # 3 Exhibits 17, # 4 Exhibit 18 (Part 1), # 5 Exhibit 18 (Part 2) # 6 Exhibits 19-21, # 7 Exhibit 22, # 8 Exhibits 23-25, # 9 Exhibit 26 (Part 1), # 10 Exhibit 26 (Part 2), # 11 Exhibit 26 (Part 3), #12 Exhibit 26 (Part 4), # 13 Exhibits 27-29, # 14 Exhibits 30-32, # 15 Exhibit 33, # 16 Exhibit 34, # 17 Exhibits 35-40, # 18 Exhibits 41-46, # 19 Exhibit 47 (Part 1), # 20 Exhibit 47 (Part 2), # 21 Exhibits 48-52, # 22 Exhibit 53 (Part 1), # 23 Exhibit 53 (Part 2), #24 Exhibit 53 (Part 3), # 25 Exhibits 54-60, # 26 Exhibit 61 (Part 1), # 27 Exhibit 61 (Part 2), # 28 Exhibits 62-63, # 29 Exhibit 64, # 30 Exhibits 65-69)(Halper, Jason) (Entered: Aug. 5, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)98Chen et al., Asymmetric Synthesis of Substituted 2-Azaspiro[3.5]nonan-1-ones: An Enantioselective Synthesis of the Cholesterol Absorption Inhibitor (+)-SCH 54016, J. Org. Chem. 61(23):8341-8343 (1996).99Chiba et al., Oxidative Metabolism of Omeprazole in Human Liver Microsomes: Cosegregation with S-Mephenytoin 4'- Hydroxylation, J. Pharmacol. Exp. Ther. 266(1):52-59 (1993).100Chiba et al., Oxidative Metabolism of Omeprazole in Human Liver Microsomes: Cosegregation with S-Mephenytoin 4′- Hydroxylation, J. Pharmacol. Exp. Ther. 266(1):52-59 (1993).101Clader et al., 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus, J. Med. Chem. 39:3684-3693 (1996).102Clader et al., Substituted (1,2-Diarylethyl)amide Acy-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity, Journal of Medicinal Chemistry 38:1600-1607 (1995).103Clader, Ezetimibe and other Azetidinone Cholesterol Absorption Inhibitors, Curr. Topics in Med. Chem. 5(3):243-256 (2005).104Clader, Ezetimibe: Chemistry-Driven Drug Discovery in the Absence of a Defined Molecular Target Schering-Plough Research Institute Visio Presentation (slides) (2005).105Clader, J.W. et al., 1995, "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity" Journal of Medicinal Chemistry 38:1600-1607.106Clader, The Discovery of Ezetimibe: A View from Outside the Receptor, J. Med. Chem. 47(1):1-9 (2004).107Claudi et al., Synthesis and Dopamine Receptor Affinities of 2-(4-Fluoro-3-Hydroxyphenyl) Ethylamine and N-Substituted Derivatives, J. Med. Chem. 33(9):2408-2412 (1990).108Complaint against Glenmark Pharmaceuticals, Inc. USA, Glenmark Pharmaceuticals Ltd., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Statement 7.1 disclosure# 2 Civil Cover Sheet # 3 Summons Glenmark, USA# 4 Summons Glenmark Ltd.)(mn, ) (Entered: Mar. 23, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).109Complaint against Impax Laboratories, Inc., filed by Schering Corporation, MSP Singapore Company, LLC. (Attachments: # 1 EXH A, # 2 EXH B, # 3 EXH C, # 4 Civil Cover Sheet, # 5 Summons)(dr, ) (Entered: Aug. 24, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-04270-JLL-CCC).110Complaint against Mylan Inc., Mylan Pharmaceuticals Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Cover letter)(kd) (Entered: Dec. 18, 2009), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:09-cv-00167-IMK).111Complaint against Mylan Inc., Mylan Pharmaceuticals Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: #1 Summons1, # 2 Summons2, # 3 Civil Cover Sheet)(Id) (Entered: Dec. 22, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).112Complaint against Mylan Pharmaceuticals, Inc. and Mylan Inc. filed by Schering Corporation and MSP Singapore Company LLC., (filed Jun. 16, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-03085-JLL-CCC).113Complaint against Mylan Pharmaceuticals, Inc. and Mylan Inc. filed by Schering Corporation and MSP Singapore Company LLC., (filed Jun. 29, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:10-cv-99-IMK).114Complaint against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Civil Cover Sheet)(dr) (Entered: Mar. 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).115Complaint against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exhibit A to Complaint, # 2 Exhibit B to Complaint, # 3 Exhibit C to Complaint, # 4 Summonsl, # 5 Summons2, # 6 Civil Cover Sheet)(Id, ) (Entered: Sep. 2, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-04473-JLL-CCC).116Complaint; summons issued against Impax Laboratories, Inc., Filed by Schering Corporation, MSP Singapore Company LLC. (slh) (Filed on Aug. 20, 2010) (Entered: Aug. 23, 2010), U.S. District Court for the Northern District of California (Civil Action No. 3:10-cv-03719-JSW).117Consent Judgment on Counterclaim, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).118Consent Judgment. Signed by Judge Jose L. Linares on May 10, 2010. (DD) (Entered: May 10, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).119Corrected Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).120Corrected Answer to Complaint, Counterclaim against Schering Corporation, MSP Singapore Company LLC by Glenmark Pharmaceuticals Ltd..(Walsh, Liza) (Entered: Jun. 7, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).121Corrected Answer to Complaint, Counterclaim against Schering Corporation, MSP Singapore Company LLC by Glenmark Pharmaceuticals, Inc. USA Ltd..(Walsh, Liza) (Entered: Jun. 7, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).122Cross Examination Transcript of Gary Thiessen, dated Sep. 15, 2009, Federal Court of Canada (Court File No. T-1610-08).123Cross-Examination transcript of John W. Clader, dated Dec. 9, 2009, Federal Court of Canada (Court File No. T-1610-08).124Cross-Examination transcript of Mark Wentland, dated Dec. 4, 2009, Federal Court of Canada (Court File No. T-1610-08).125Curtis et al., Double-blind, placebo-controlled cross-over trial of cholestyramine an bezafibrate in the treatment of monogenic familial hypercholesterolaemia (FH), Atherosclerosis 68:271 (1987).126D. Roger Hlingworth, 1988, "An Overview of Lipid-Lower Drugs" Drugs 36:63:71.127Davidson and Eastham, Acute Liver Necrosis Following Overdose of Paracetamol, Br. Med. J. 2(5512):497-499 (1966).128Davis et al., Species Differences in Hepatic Glutathione. Depletion, Covalent Binding and Hepatic Necrosis After Acetaminophen Life Sci., 14(11):2099-2109 (1974).129Davis et al., The hypercholesterolemic activity of the potent cholesterol absorption inhibitor SCH 58235 alone and in combination with HMG CoA reductase inhibitors, XII Int'l Symposium on Drugs Affecting Lipid Metabolism, Abstract, p. 62 (1995).130Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3�Hydroxy-3�Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, Metabolism 50(10):1234-1241 (2001).131Davis, Harry R.; Declaration of Harry R. Davis under 37 C.F.R, 1.132 dated Jan. 27, 1997 from file history of U.S. Appl. No. 08/449,978.132Davis, Harry R.; Declaration of Harry R. Davis under 37 C.F.R, 1.132 dated May 8, 1996 from file history of U.S. Appl. No. 08/257,593.133DeBernardis et al., Conformationally Defined Adrenergic Agents. 1. Design and Synthesis of Novel alpha2 Selective Adrenergic Agents: Electrostatic Repulsion Based Conformational Prototypes, J. Med. Chem. 28(10):1398-1404 (1985).134DeBernardis et al., Conformationally Defined Adrenergic Agents. 1. Design and Synthesis of Novel α2 Selective Adrenergic Agents: Electrostatic Repulsion Based Conformational Prototypes, J. Med. Chem. 28(10):1398-1404 (1985).135Declaration of Antonio M. Gotto, dated Sep. 29, 2010, U.S. District Court cm the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).136Declaration of Gerald S. Brenner, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES).137Declaration of James Suh in Support of Plaintiffs' Opening Claim Construction Brief, dated Sep. 29, 2010, U.S District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).138Declaration of Srilakshmi M. Ravi (Supplemental) by Mylan Pharmaceuticals Inc., (Attachments: # 1 Exhibit 36 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 2 Exhibit 37 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 3 Exhibit 38 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 4 Exhibit 39 to the Declaration (Supplemental) of Srilakshmi M. Ravi), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).139Declaration of Srilakshmi M. Ravi, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).140Defendant Impax Laboratories, Inc.'s Answer, Affirmative Defenses, Counterclaims and Jury Demand, dated Sep. 24, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04270 (JLL-CCC)).141Defendant Mylan Pharmaceuticals Inc.'s Amended Invalidity and Non-Infringement Contentions Pursuant to Local Patent Rules 3.3 and 3.6 (redacted for Mylan confidential information), dated Sep. 9, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).142Defendant Mylan Pharmaceuticals Inc.'s Answer To Plaintiffs' Complaint, Separate Defenses and Counterclaims, dated Jul. 28, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-03085 (JLL-ES)).143Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-3), dated Jul. 30, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).144deGennes et al., Long-term (over 5 years) treatment of primary hyperlipidemia by fenofibrate alone or with cholestyramine, Treatment of Hyperlipoproteinemia, (Carlson and Olsson, eds.), Raven Press, NY, pp. 175-180 (1984).145Dembowski and Davidson, Statin and Ezetimibe Combination Therapy in Cardiovascular Disease. Curr. Opin. Endocrinol. Diabetes Obes. 16(2):183-188 (2009).146Deposition of Antonio M. Gotto, Jr., M.D., D. Phil., dated Nov. 23, 2009, Federal Court of Canada (Court File No. T-1610-08).147Deposition of Neal Castagnoli, Ph.D., dated Nov. 6, 2009, Federal Court of Canada (Court File No. T-1610-08).148Deposition Transcript of Adriano Afonso, dated Oct. 21, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).149Deposition Transcript of Anita Magatti, dated Jan. 7, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).150Deposition Transcript of Cecil B. Pickett, dated Nov. 14, 2008. U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).151Deposition Transcript of Dorothy Auth, dated Jan. 9, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).152Deposition Transcript of Dr. John Sutherland (Cross-examination), dated Oct. 20, 2009, Federal Court of Canada (Cout File No. T.1610-08).153Deposition Transcript of Dr. Wayne Vaccaro, dated Jun. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).154Deposition Transcript of Duane Burnett, dated Sep. 25, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).155Deposition 'Transcript of Harry Davis, dated Oct. 14, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).156Deposition Transcript of James Nelson, dated Oct. 29, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).157Deposition Transcript of James Nelson, dated Oct. 30, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).158Deposition Transcript of John Clader, Ph.D, dated Dec. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).159Deposition Transcript of Kevin Alton, dated Sep. 9, 2008, U.S. District Court for the District of New Jersey (Civil Action no. 07-cv-1334 {JLL/ES)).160Deposition Transcript of Leslie Z. Benet, Ph.D., dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08).161Deposition Transcript of Margaret Van Heek, dated Sep. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).162Deposition Transcript of Nathan Yumibe, dated May 9, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).163Deposition Transcript of Stuart B. Rosenblum, dated Dec. 4, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).164Deposition Transcript of Stuart B. Rosenblum, dated Dec. 5, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).165Deposition Transcript of Stuart Rosenbaum, dated Feb. 10, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).166Deposition Transcript of Sundeep Dugar, Ph.D., dated May 2, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).167Development of new stereoisomeric drugs, May 1, 1992, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm122883.htm, downloaded Aug. 10, 2010.168Di Giulio, et al., Encapsulation of Ampicillin in Reverse-Phase Evaporation Liposomes: A Direct Evaluation by Derivative Spectrophotometry, Int. J. Pharm. 74:183-188 (1991).169Dodd et al., Metabolism and Pharmacokinetics of Selected Halon Replacement Candidates, Toxicol. Lett. 68(1-2):37-47 (1993).170Doherty et al., Design and Synthesis of Potent, Selective, and Orally Active Fluorine-Containing Renin Inhibitors, J. Med. Chem. 35(1):2-14 (1992).171Dolle et al., ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Sulfoximine and 3-Hydroxy-beta-Lactam Containing Analogues of Citric Acid as Potential Tight-Binding Inhibitors, J. Med. Chem. 35(26):4875-4884 (1992).172Dolle et al., ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Sulfoximine and 3-Hydroxy-β-Lactam Containing Analogues of Citric Acid as Potential Tight-Binding Inhibitors, J. Med. Chem. 35(26):4875-4884 (1992).173Dollery et al., (eds) Therapeutic Drugs, vol. 1, Churchill Livingstone, Edinburgh (1991).174Dorland's Illustrated Medical Dictionary, 30th Ed., W.B. Saunders & Co., Canada, p. 1513 (2003)-"prodrug".175Dorland's Illustrated Medical Dictionary, 30th Ed., W.B. Saunders & Co., Canada, p. 1513 (2003)—"prodrug".176Drazen et al., Cholesterol Lowering and Ezetimibe, N. Eng. J. Med. 358(14):1507-1508 (2008).177Drug Information, Baycol Information, Center for Drug Evaluation and Research, 2001, http://www.fda.gov/cder/drug/infopagelbaycol/default.htm, downloaded Apr. 15, 2009.178Dugar et al., Amides of Piperidine, Morpholine and Piperazine Substituted 1-Phenylethylamines: Inhibitors of AcylCoA:cholesterol Acyltransferase (ACAT) Activity in vitro and in vivo, Bioorg. Med. Chem., 3(9):1231-1236 (1995).179Dugar et al., Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461, Bioorg. Med. Chem. Lett. 5(24)2947-2952 (1995).180Dugar et al., Metabolism and structure activity data based drug design; discovery of (-) SCH 53079 an analog of the potent cholesterol absorption inhibitor (-) SCH 48461, Bioorg. Med. Chem. Lett. 6(11):1271-1271 (1996).181Dugar et al., N-Oleayl-l,2,3,4-Tetrahydroisoquinolines as Conformationally Restricted Inhibitors of Acyl-CoA:Cholesterol Acyl Transferase (ACAT), Bioorg. Med. Chem. Lett., 3(4):571-576 (1993).182Dugar et al., Substituted 2-Azaspiro[5.3]nonan-1-ones as Potent Cholesterol Absorption Inhibitors: Defining a Binding Conformation for SCH 48461, J. Med. Chem. 38(25):4875-4877 (1995).183DuJovne et al., Probucol with colestipol in the teatment of hypercholesteolemia, Ann. Intern. Med. 100:477-482 (1984).184Dujovne et al., Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study, J. Clin Pharmacology 41:70-78 (2001) (Abstract only).185Dujovne et al., Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study, J. Clin Pharmacology 41:70-78 (2001) (full copy) (cited in abstract form as document C106 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).186Durst et al., Metallation of N-Substituted beta-Lactams, A Method for the Introduction of 3-Substituents into beta-Lactams, Canadian Journal of Chemistry, 50:3196-3201 (1971).187Durst et al., Metallation of N-Substituted β-Lactams, A Method for the Introduction of 3-Substituents into β-Lactams, Canadian Journal of Chemistry, 50:3196-3201 (1971).188Duschinsky et al., The Synthesis of 5-Fluoropyrimidines, J. Am. Chem. Soc. 79:4559-4560 (1957).189Dysken et al., Fluphenazine Pharmacokinetics and Therapeutic Response, Psychooharmacology 73:205-210 (1981).190East et al., Combination drug therapy for treatment of patients with familial combined hyperlipidemia resulting in combined hypertriglyceridemia and hypercholesterolemia, Arteriosclerosis 6:544A (1986).191Eger et al., Is Enfiurane Hepatotoxic? Anesth. Analg. 65(1)21-30 (1986).192El Masry, Studies in Detoxication. 69. The metabolism of alkylbenzenes: n-propylbenzene and n-butylbenzene with further observations of ethylbenzene, Biochem J. 64(1):50-56 (1956).193Elliott, The Role of Fluorine in the Development of Central Nervous System Agents in Biomedicinal Aspects of Fluorine Chemistry (R. Fuller and Y. Kobayashi, eds.), Elsevier Biomedical Press, New York, pp. 55-74, (1982).194Erlenmeye et al., Justus Liebigs Annalen der Chemie, Liepzig, C.F. Wintersche Verladshandluna, pp. 51-123 (1907), vol. 356.195Expert Report of Christopher A. Vellturo. Ph.D., dated Apr. 17, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).196Expert Report of Clayton Heathcock, Ph.D., dated Feb. 25, 2009, U.S, District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).197Expert Report of Dr. Ronald Hines, dated Feb. 27, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).198Expert Report of F. Peter Guengerich, dated Apr. 16, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).199Expert Report of Paul Ortiz de Montellano, Ph.D., dated Mar. 2, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).200Expert Report of Richard Bruce van Breernen, Ph.D., dated Mar. 2, 2009, U.S District Court for the District of New Jersey (Civil Action No. 07-cv-1337 (JLL/ES)).201Expert Report of Ronald G. Brisbois, Ph.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).202Expert Report of Stephen G. Kunin, Esq. , dated Apr. 17, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/Es)).203Expert Report of W. Virgil Brown, M.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).204Expert Report of William R. Roush, Ph.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).205Filler, Organofluorine Chemicals and their Industrial Applications (Banks, R. E, ed.), Ellis Horwood Ltd. Publishers, Chichester, Ch. 6 Fluorine-containing Drugs (1979).206Final Pretrial Order, U.S. District Court for the District of New Jersey (redacted for Glenmark confidential information and personal information of witnesses), signed Mar. 11, 2010 (Civil Action No. 07-cv-1334 (JLL/ES)).207First Amended Answer to Complaint by Glenmark Pharmaceuticals Ltd. (Walsh, Liza) (Entered: Mar. 10, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES).208First Amended Answer to Complaint by Glenmark Pharmaceuticals, Inc.USA.(Walsh, Liza) (Entered: Mar. 10, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).209Frey and Frey, Urinary 6 β-Hydroxyprednisolone Excretion Indicates Enhanced Prednisolone Catabolism, J. Lab. Clin. Med. 101(4):593-604 (1983).210Fried and Sabo, 9α-Fluoro Derivatives of Cortisone and Hydrocortisone, J. Am. Chem. Soc. 76:1455-1456 (1954).211Fried et al., 10,10-Difluoro-13-Dehydroprostacyclin: A Chemically and Metabolically Stabilized Potent Prostacyclin, J. Med. Chem. 23(3):234-237 (1980).212Fried et al., Synthesis and Properties of 7,7-Difluoro Derivatives of the 2,6-Dioxa[3.1.1] bicycloheptane Ring System Present in Thromboxane A2, J. Am. Chem. Soc. 106:3871-3872 (1984).213G. George et al., 1985 "3-(T-Hydroxyethyl)-2-Azetidinones From 3-Hdyroxy-butyrates and N-Arylaldimines" Tetrahedron Letters, vol. 26, No. 33 pp. 3903-3906.214Garcia-Calvo et al., The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1), Proc. Natl. Acad. Sci. USA 102(23):8132-8137 (2005).215Gazi et al., Effect of Ezetimibe in Patients Who Cannot Tolerate Statins or Cannot Get to the Low Density Lipoprotein Cholesterol Target Despite Taking a Statin, Curr. Med. Res. Opin. 23(9):2183-92 (2007).216Generic Pharmaceutical Association. Facts at a Glance. http://www.gphaonline.org/about-gpha/about-generics/facts � 2010.217Georg and Gill, Stereo—and Enantio-controlled synthesis of chiral intermediates for the total synthesis of thienaycin and related β-Lactam antibiotics from 3-hydroxybutyrates, J. Chem. Soc., Chem. Comm. pp. 1433-1435 (1985).218Georg et al., 3-(1′-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines, Tetrahedron Letters 26(33):3903-3906 (1985).219Georg et al., 3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines, Tetrahedron Letters 26(33):3903-3906 (1985).220Georg et al., An Impoved Mehod For The Stereoselective Synthesis Of B-Lactams From Carboxylic Acids And Imines, Tet. Lett. 32(5):581-584(1991).221Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Amended Responses to Plaintiffs' Interrogatories (Nos. 1-17), dated Mar. 6, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).222Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Supplemental Response To Plaintiffs' Interrogatory No. 1, dated May 11, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).223Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Supplemental Response To Plaintiffs' Interrogatory No. 4, dated Nov. 6, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).224Goldstein and Brown, Cholesterol: A Century of Research. HHMI Bulletin, vol. 16, No. 3, Sep. 2003.225Gootz et al., "Pharmacokinetic Studies in Animals of a New Parenteral Penem CP-65,207 and its Oral Prodrug Ester," J. Antibiot. 43(4):422-432 (1990).226Gotto, Over-The-Counter Statins Are Worth Considering in Primary Prevention of Cardiovascular Disease, Circulation 114:1310-1314 (2006).227Grundy et al., Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation 110(2):227-239 (2004).228Grundy et al., Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in Heterozygous familial hypercholesterolemia, Ann. Intern. Med., 103:339-343 (1985).229Guengerich and MacDonald, Chemical Mechanism of Catalysis by Cytochromes P-450: A Unified View, Acc. Chem. Res. 17:9-16 (1984).230H. Otto et al., 1983, "Darstellung und Stereochemic von 3-(α-Hydroxybenzyl)-1,4-diphenyl-azetidononen", Liebigs Ann. Chem. 1152-1161.231Halloran et al., An Examination of the Importance of 24-Hydroxylation to the Function of Vitamin D During Early Development, Endocrinology 108(6):2067-2071 (1981).232Hansch and Leo, Cluster Analysis and the Design of Congener Sets, in Substituent Constants for Correlation Analysis in Chemistry and Biology, John Wiley & Sons, NY, Ch. 6, 48-54 (1979).233Harris and Anders, Metabolism of the Hydrochlorofluorocarbon 1,2-Dichloro-1,1-Difluoroethane, Chem. Res. Toxicol. 4(2):180-186 (1991).234Harris et al., Pentahaloethane-Based Chlorofluorocarbon Substitutes and Halothane: Correlation of In Vivo Hepatic Protein Trifluoroacetylation and Urinary Trifluoroacetic Acid Excretion with Calculated Enthalpies of Activation, Chem. Res. Toxicol. 5(5):720-725 (1992).235Harris et al., Tissue Acylation by the Chlorofluorocarbon Substitute 2,2-Dichloro-1,1,1-Trifluoroethane, Proc. Natl. Acad. Sci. USA 88(4):1407-1410 (1991).236Harrison et al., Metabolic Defluorination of 5-Fluoro-Amodiaquine in the Rat, Br. J. Clin. Pharmacol. 34:148P-149P (1992).237Hart and Ha, The Ester Enoiate-Imine Condensation Route to β-Lactams, Chem. Rev. 89(7):1447-1465 (1989).238Hart et al., 1985 "An Enantioselective Approach to Carhapenen Antibodies: Formal Synthesis of (+)-Thienamycin" Tetrahedron Letters, vol. 26, No. 45 pp. 5493-5496.239Hart et al., An Enantioselective Approach to Carbapenen Antibodies: Formal Synthesis of (+)-Thienamycin, Tetrahedron Letters, 26(45):5493-5496 (1985).240Harwood, H. James, 1993, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β-tigogenin cellobioside (CP-88818;tiqueside)1 " Journal of Lipid Research 34:377-395.241Harwood, Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin beta-tigogenin cellobioside (CP-88818; liqueside), Journal of Lipid Research 34:377-395 (1993).242Harwood, Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β-tigogenin cellobioside (CP-88818; liqueside), Journal of Lipid Research 34:377-395 (1993).243Hearing Transcript before the Honorable Jose L. Linares (Markman Hearing), dated Jul. 29, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).244Hecht et al., Comparative Mutagenicity, Tumor-Initiating Activity, Carcinogenicity, and In Vitro Metabolisrn of Fluorinated 5-Methylchrysenes, J. Natl. Cancer Inst. 63(3):855-861 (1979).245Hecht et al., Reduction of Tumorigenicity and of Dihydrodiol Formation by Fluorine Substitution in the Angular Rings of Dibenzo(a,i) Pyrene, Cancer Res. 41(11 Pt. 1):4341-4345 (1981).246Heidelberger et al., Fluorinated Pyrimidines, a New Class of Tumour-Inhibitory Compounds, Nature 179(4561):663-666 (1957).247Heidelberger, The Nucleotides of Fluorinated Pyrimidines and Their Biological Activities, in Carbon-Fluorine Compounds: Chemistry, Biochemistry and Biological Activities, (K. Elliot, ed.), Associated Scientific Publishers, Amsterdam, pp. 125-140 (1972).248Herper, Behind Zetia's curtain, http://www.forbes.com/2002/10/31/cx, downloaded Apr. 29, 2010.249High Blood Cholesterol: What you need to know, http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm—downloaded Aug. 10, 2010.250Hitt et al., Metabolism of Isoflurane in Fischer 344 Rats and Man, Anesthesiology 40(1):62-67(1974).251Hobbs et al., Pharmacokinetics of prazosin in man, J. Clin. Pharmacol. 18(8):402-6 (1978) (full copy) (cited in abstract form as document C143 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,3741).252Hobbs et al., Pharmacokinetics of prazosin in man, J. Clin. Pharmacol. 18(8):402-6 (1978) Abstract only.253Hodgkins and Megarity, A Study of Benzyl Free Radical and Substituted Benzyl Free Radicals, J. Amer. Chem. Soc. 87(23):5322-5326 (1965).254Hoeg et al., The Effects of Mevinolin and Neomycin Alone and in Combination on Plasma Lipid and Lipoprotein Concentrations in Type II Hyperlipoproteinemia, Atherosclerosis 60:209-214 (1986).255Hoeg, Combination Drug Therapy, in Drug Treatment of Hyperlipidemia, Ch. 10, (Rifkind, Ed.), Marcel Dekker, Inc., pp. 215-231 (1991).256Hoekman et al., Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Add delta-Lactones, J. Agric, Food Chem. 30:920-924 (1982).257Hoekman et al., Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Add δ-Lactones, J. Agric, Food Chem. 30:920-924 (1982).258Horie et al., Hypolipidemic effects of NB-598 in dogs, Atherosclerosis 88:183-192 (1991).259Horie, M. et al. 1991, "Hypolipidemic effects of NB-598 in dogs" Atherosclerosis 88:183-192.260Huberman and Slaga, Mutagenicity and Tumor-Initiating Activity of Fluorinated Derivatives of 7,12-Dimethylbenz(a)Anthracene, Cancer Res. 39(2 Pt. 1):411-414 (1979).261Hughes and Saunders, Enzymatic Rupture of a C-F Bond, Chem. Ind. (London) 1265 (1954).262Humphrey and Smith, Role of metabolism ad pharmacokinetic studies in the discovery of new drugs—present and future perspectives, Xenobiotica 22(7):743-755 (1992).263Husain et al., Fluoride Elimination from Substrates in Hydroxylation Reactions Catalyzed by p-Hydroxybenzoate Hydroxylase, J. Biol. Chem. 255(9):4189-4197 (1980).264Illingworth and Bacon, Hypolipidemic Effects of HMG-CoA Reductase Inhibitors in Patients with Hypercholesterolemia, Am. J. Cardiol. 60(12):33g-42g (1987).265Illingworth et al., Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia, Lancet 1(8215):296-298 (1981).266Illingworth et al., Long-Term Experience with HMG-CoA Reductase Inhibitors in the Therapy of Hypercholesterolemia, Atherosclerosis Revs. 18:161-187 (1988).267Illingworth, An Overview of Lipid-Lower Drugs, Drugs 36:63:71 (1988).268Illingworth, Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia, Ann. Intern. Med. 101:598-604 (1984).269Intelligence.360, Global Pharmaceutical Perspectives, Making sense of the year—and what lies ahead—in a time of unprecedented challenge and opportunity, 2006.270International Search Report dated Dec. 8, 1994 in PCT/US94/10099.271Jackevicius, C. A. et al., "Long-term Trends in Use of and Expenditures for Cardiovascular Medications in Canada," Canadian Medical Association Journal, 181(1-2):E19-E28, Jul. 7, 2009 (cited as document C156 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).272Jamali, Stereochemically Pure Drugs—An Overview, Drug Stereochemistry, in Analytical Methods and Pharmacology. Ch. 14, pp. 375-384 (1993).273Jerina et al., Carcinogenicity of Benzo[a]Pyrene, in Drug Design and Adverse Reactions (II. Bundgaard, P. Juul, and H. Kafod, eds.), Academic Press, New York, pp. 261-275 (1977).274Jeu and Cheng, Pharmacology and Therapeutics of Ezetimibe (SCH 58235), a Cholesterol-Absorption Inhibitor, Clin. Ther. 25(9):2352-2387 (2003).275Joint Claim Construction and PreHearing Statement, dated Jul. 23, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-0v-06383 (JLL/ES)).276Jones et al. Biotransformation and Hepato-Renal Function in Volunteers After Exposure to Desflurane (1-653), Br. J. Anaesth. 64(4):482-487 (1990).277Joseph L. Witztum, M.D., 1989, "CUrrent Approaches to Drug Therapy for the Hyercholesterolemic Patient" Circulation 80:1101-1114.278Kane et al., Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen, New Engl. J. Med. 304(5):251-258 (1981).279Kastelein et al., Simvastatin with or without ezetimibe in Familial Hypercholesterolemia, New Eng. J. Med. 358(14):1431-43 (2008).280Kastelein, Statin Therapy with Ezetimibe or Niacin in High-Risk Patients, New Eng. J. Med., 361:2180-2183 (2009).281Kaufman, The enzymic conversion of 4-fluorophenylalanine to tyrosine, Biochim, Biophys. Acta 51:619-621 (1961).282Kawase et al., Mechanism of Autoxidation of 5,7-Dihydroxytryptamine: Effect of Fluorine Substitution at Positions 4 and/or 6, Chem. Pharm, Bull 38(11):2939-2946 (1990).283Kenna et al., Metabolic Basis for a Drug Hypersensitivity: Antibodies in Sera From Patients With Halothane Hepatitis Recognize Liver Neoantigens that Contain the Trifluoroacetyl Group Derived from Halothane, J. Pharmacol. Exp. Ther. 245(3):1103-1109 (1988).284Kimura et al., Structure-activity relationship of a series of phenylureas linked to 4-phenylimidazole. Novel potent inhibitors of acyl-CoA:cholesterol O-acyltransferase with antiatherosclerotic activity. 2., J. Med. Chem. 36(11):1641-1653 (1993).285Kimura et al., Structure-Activity Relationship of N-[2-(Dimethylamino)-6-[3-(5-Methy1-4- Phenyl-1H-Imidazol-1-yl)Propoxy]Phenyl]-N'-Pentylurea and Analogues. Novel Potent Inhibitors of Acyl-CoA: Cholesterol O-Acyltransferase with Antiatherosclerotic Activity, J. Med. Chem. 36(11):1630-1640 (1993).286Kirk et al., Syntheses and adrenergic agonist poperies of ring-fluorinated isoproterenols, J. Med. Chem. 25(6):680-684 (1982).287Kirk et al., Synthesis and adrenergic activity of ring-fluorinated phenylepherines, J. Med. Chem. 29(10):1982-1988 (1986).288Kirkup et al., (-)-SCH 57939: Synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor, Bioorg. Med. Chem. Lett. 6(17):2069-2072 (1996).289Kitteringham et al., Conjugation of dinitrofluorobenzene to plasma proteins in vivo in the rat, Drug Metab. Dispos. 20(5):625-631 (1992).290Kobayashi and Taguchi, Fluorinated Vitamin D3 Analogs Syntheses and Biological Activites, in Biomedical Aspects of Fluorine Chemistry (R. Filler and Y. Kobayashi, eds.), Associated Scientific Publishers, Amsterdam, pp, 33 (1982).291Koblin et al., I-653 Resists Degradation in Rats, Anesth. Analg. 67(6):534-538 (1988).292Kollonitsch et al., Selective Inhibitors of biosynthesis of Aminergic Neurotransmitters, Nature 274(5674):906-908 (1978).293Kong et al., Comparisons of Anti-Human Immunodeficiency Virus Activites, Cellular Transport, and Plasma and Intracellular Pharmacokinetics of 3′-Fluoro-3′-Deoxythymidine and 3′-Azido-3′-Deoxythymidine, Antimicrob. Agents Chernother, 36(4):808-818 (1992).294Kripalani et al., Metabolism of Triamcinolone Acetonide-21-Phosphate in Dogs, Monkeys, and Rats, J. Pharm. Sci. 64(8):1351-1359 (1975).295Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther. 1989;45:28-33.296Kropp et al., Meabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I Antimicrob. Agents Chemother. 22(1):62-70 (1982).297Kuo et al., Effects of Combined Probucol-Colestipol Treatment for Familial Hypercholesterolemia and Coronary Artery Disease, Am. J. Cardiol. 57:43H-48H (1986).298Landsberg, Can Entropy and "Order" Increase Together? Physics Letters 102A(4):171-173 (1984).299Landsberg, Is Equilibrium Always an Entropy Maximum? J. Stat. Physics 35(1/2):159-169 (1984).300Lees et al., Therapy of Hypercholesterolemia with Mevinolin and Other Lipid-Lowering Drugs, Arteriosclerosis 6:544 (1986).301Lehninger et al., Principles of Biochemistry, Second Edition (Worth Publishers, NY), Table of Contents (1993).302Letter from counsel for Mylan Pharmaceuticals Inc. to MSP Singapore Co., Schering Corp,, and Merck & Co., Inc. re: Notification of Certification of Noninfringement and/or Invalidity for U.S. Patent Nos. 5,846,966 and RE37,712 Pursuant to �505(j)(2)(B)(ii) of the U.S Federal Food, Drug and Cosmetic Act. dated Nov. 5, 2009.303Letter from counsel for Mylan Pharmaceuticals Inc. to MSP Singapore Co., Schering Corp., and Merck & Co., Inc. re: Notification of Certification of Noninfringement and/or Invalidity for U.S. Patent Nos. 5,846,966 and RE37,712 Pursuant to �505(j)(2)(B)(ii) of the U.S Federal Food, Drug and Cosmetic Act, dated May 25, 2010.304Letter from Defendants In Response to Plaintiffs' Aug. 1 Suppl Briefing On Claim Construction. (Ruiz, Hector) (Entered: Aug. 7, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).305Letter from Defendants in Response to Plaintiffs' Aug. 8, 2008 Letter On Claim Construction Issues. (Ruiz, Hector) (Entered: Aug. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).306Letter from Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd. regarding Plaintiffs' Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13.. (Walsh, Liza) (Entered: May 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).307Letter from Impax Laboratories, Inc. to MSP Singapore Co. LLC, Merck & Co., Inc. and Schering Corporation. re: Paragraph IV Patent Certification Notice for U.S. Patent Nos. RE37,712 and 5,846,966, dated Jul. 9, 2010.308Letter from Liza M. Walsh to the Honorable Jose L. Linares. (Attachments: # 1 Brief in Support of Proposed Claim Interpretations# 2 Declaration of Agnes Antonian # 3 Text of Proposed Order # 4 Certificate of Service)(Walsh, Liza) (Entered: Jan. 14, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).309Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief. (Attachments: # 1 Brief# 2 Proposed Order# 'Certification of Service# 4 Krause Declaration, Ex. A# 5 Krause Declaration, Ex. B# 6 Krause Declaration, Ex. C Part 1# 7 Krause Declaration, Ex. C Part 2# 8 Krause Declaration, Ex. C Part 3# 9 Krause Declaration, Ex. D Part 1# 10 Krause Declaration, Ex. D Part 2# 11 Krause Declaration, Ex. D Part 3# 12 Krause Declaration, Ex. D Part 4# 13 Krause Declaration, Ex. E Part 1# 14 Krause Declaration, Ex. E Part 2# 15 Krause Declaration, Ex. E Part 3# 16 Krause Declaration, Ex. E Part 4# 17 Krause Declaration, Ex. E Part 5# 18 Krause Declaration, Ex. E Part 6# 19 Krause Declaration, Exs. F-G# 20 Krause Declaration, Exs. H-O# 21 Krause Declaration, Exs. P-Q)(Halper, Jason) (Entered: Jan. 14, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).310Letter from Plaintiffs in Reply to Glenmark's Aug. 6, 2008 Letter re Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief, (Halper, Jason) (Entered: Aug. 8, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).311Letter from Plaintiffs in Response to Defendants' Notice of Supplemental Authority re Notice by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) of Supplemental Authority in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue). (Halper, Jason) (Entered: Jan. 14, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).312Letter from Plaintiffs regarding July 29 Markman Hearing re Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief, (Halper, Jason) (Entered: Aug. 1, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).313Letter from Plaintiffs Schering Corporation and MSP Singapore Company LLC to Judge Esther Salas seeking Modification of Proposed Claim Constructions Provided inJoint Claim Construction and Prehearing Statement (Proposed Order attached), dated Sep. 14, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).314Letter from Teva Pharmaceuticals USA, Inc, to Merck & Co, Inc., MSP Singapore Company, LLC and Schering Corporation re: Notice of ANDA No. 078724 Concerning Ezetimibe Tablets, 10 mg with Paragraph IV Certification Concerning U.S. Patent Nos. 5,846,966 and RE37,721 and 7,612,058, dated Jul. 20, 2010.315Letter from Teva Pharmaceuticals USA, Inc. to Merck & Co, Inc., MSP Singapore Company, LLC and Schering Corporation re: Notice of ANDA No. 200909 Concerning Ezetimibe/Simvastatin Tablets, 10 mg/80 mg with Paragraph IV Certification Concerning U.S. Patent Nos. 5,846,966 and RE37,721, dated Feb. 19, 2010.316Li et al., Catechol Formation of Fluoro—and Bromo-Substituted Estradiols by Hamster Liver Microsomes. Evidence for Dehalogenation, Mol. Pharmacol. 27(5):559-565 (1985).317Liehr, 2-Fluoroestradiol, Separation of Estrogenicity from Carcinogenicity, Mol. Pharmacol. 23(2)278-281 (1983).318Lien, Structure-Absorption-Distribution Relationships: Significance for Drug Design, in Drug Design, vol. V, (Ari�ns, Ed.) Academic Press, NY, pp. 81-132 (1975).319Lloyd-Jones et al., Heart Disease and Stroke Statistics—2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, pp. e22-e181 (Jan. 27, 2009) (downloaded from circ.ahajournals.org on Apr 14, 2009).320Low and Castagnoli, "Metabolic changes of drugs and related organic compounds," In Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, Jaime N. Delgado and William A. Remers, Eds., 9th Ed., J.B. Lippincott Company, pp. 45-127 (1991).321Low and Castagnoli, "Metabolic changes of drugs and related organic compounds," In Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, Robert F. Doerge, Ed., 8th Ed., J.B. Lippincott Company, pp. 55-127 (1982).322Low and Castagnoli, Drug Biotransformations, in Burger's Medicinal Chemistry, 4th Ed., Part I, The Basis of Medicinal Chemistry, (Wolff, ed.), John Wiley & Sons, NY, pp. 108-226 (1980).323Low and Castagnoli, Metabolic Changes of Drugs and Related Organic Compounds, in Wilson and Gisvolds Textbook of Organic Medicinal and Pharmaceutical Chemistry, 9th Ed., Ch. 3, (Delgado and Remers, Eds.), pp. 45-127 (1991).324M. Hoekman et al., 1982, "Synthesis of Homologues of 4.5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Acid-Lactones", J. Agric. Food Chem., 30:920-924.325Mabuchi et al., Reduction of serum cholesterol in heterozygous patients with familial hyperchalesterolemia, New Eng. J. Med, 308:609-613 (1983).326Malloy et al., Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia, Ann. Intern. Med., 107:616-623 (1987).327Mann et al., Probucol in patients resistant to the lipid lowering effects of cholestyramine, Lancet Feb. 21;1(8217):450-451 (1981).328Mann, Modern Methods for the Introduction of Fluorine into Organic Molecules: An Approach to Compounds with Altered Chemical and Biological Activities, Chem. Soc. Rev. 16:381-436 (1987).329Manuel et al., Burden of cardiovascular disease in Canada, Can J. Cardiol. 19(9):997-1004.330March, Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, Fourth Edition (Wiley 1992) University of Michigan, Table of Contents.331Masood et al., 2′-Fluoro-2,3′-Dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2′,3′-Dideoxyadenosine, Mol. Pharmacol, 37(4):590-596 (1990).332Matthes et al., Phosphorylation, Anti-HIV Activity and Cytotoxicity of 3′-Fluorothymidine, Biochem. Biophys. Res. Commun. 153(2):825-831 (1988).333Mauro and Tuckerman, Ezetimibe for Management of Hypercholesterolemia, Ann. of Phormacother. 37:839-848 (2003).334Mayrhofer et al., Simple Prep. of 3-Benzylidene-2-azetilidinones, Synthesis 247-8 (1980).335Mazze et al., Inorganic Fluoride Nephrotoxicity: Prolonged Enflurane and Halothane Anesthesia in Volunteers, Anesthesiology 46(4):265-271 (1977).336Mazze et al., Methoxyflurane Metabolism and Renal Dysfunction: Clinical Correlation in Man, Anesthesiology 35(3):247-252 (1971).337Mazze et al., Renal Effects and Metabolism of Isoflurane in Man, Anesthesiology 40(6):536-542 (1974).338McCarthy et al., 4′,5′-Unsaturated 5′-Fluoroadenosine Nucleosides: Potent Mechanism-Based Inhibitors of S-Adenosyl-L-Homocysteine Hydrolase, J. Am. Chem. Soc. 111:1127-1128 (1989).339McCarthy, New Approaches to Atherosclerosis: An Overview, Med. Res. Rev. 13(2):139-159 (1993).340McGill et al., Natural History of Human Atherosclerotic Lesions, Atherosclerosis and its Origin, (Sandler and Bourne, eds.), pp. 39-65 (1963).341McKittrick et al., Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, Bioorg. & Med. Chem Lett. 6(16):1947-1950 (1996).342McKittrick et al., Synthesis of C3 Heteroatom-Substituted Azetidinones that display potent cholesterol absorption inihibitory activity, J. Med. Chem. 41(5):752-759 (1998).343Memorandum of Fact and Law of the Respondent NovoPharm Limited ("TEVA"), dated Mar. 29, 2010, Federal Court of Canada (Court File No. T-1610-08).344Merck Manual of Diagnosis & Therapy, 25th Ed., Berkow (ed.), Merck & Co., Inc., at p. 2430.—"pharmacokinetics" (1987).345Merriam-Webster's New Collegiate Dictionary, 8th ed., Merriam-Webster, Inc.—"administering" (1981).346Michalek et al., Pharmacokinetics of TCDD in veterans of Operation Ranch Hand; 10-year-follow-up, Journal of Toxicology and Environmental Health 52(6):557-558 (1997).347Miller and Miller, The Carcinogenicity of Fluoro Derivatives of 10-Methyl-1,2-Benzanthracene. I. 3- and 4′-Monofluoro Derivatives, Cancer Res. 20:133-137 (1960).348Minagawa et al., Identification and Quantification of 6 β-Hydroxydexamethasone as a Major Urinary Metabolite of Dexamethasone in Man, Steroids 47(2-3):175-188 (1986).349Molgaard et al., Long-term Efficacy and Safety of Simvastatin Alone and in Combination Therapy in Treatment of Hypercholesterolaemia, Atherosclerosis 91:S21-S28 (1991).350Montgomery et al., Synthesis and Biological Evaluation of 2-Fluoro-8-Azaadenosine and Related Compounds, J. Med. Chem. 26(10):1483-1489 (1983).351Morgan et al., Oxidative Dehalogenation of 2-Fluoro-17 α-Ethynyloestradiol in vivo. A Distal Structure-Metabolism Relationship of 17 α-Ethynylation, Biochem. Pharmacol. 44(9):1717-1724 (1992).352Morgan et al., The Metabolism of 2- and 4-Fluoro-17 β-Oestradiol in the Rat and its Implications for Oestrogen Carcinogenesis, Biochem. Pharmacol. 43(5):985-993 (1992).353Morinelli et al., Difluorothromboxane A2 and Stereoisomers: Stable Derivatives of Thromboxane A2 with Differential Effects on Platelets and Blood Vessels, Proc. Natl. Acad. Sci. U.S.A. 86(14):5600-5604 (1989).354Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) by Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Statement of Undisputed Material Facts, # 2 Confidential Memorandum of Law [Redacted], # 3 Confidential Declaration of Robert L. Jacobson [Redacted], # 4 Confidential Exhibits A-E [Redacted], # 5 Confidential Exhibits F-K [Redacted], # 6 Proposed Order, # 7 Certificate of Service)(Walsh, Liza) Modified on Apr. 12, 2010 (DD,). (Entered: Jul. 1, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).355Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13 by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Brief in Support of Plaintiffs' Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13, # 2 Text of Proposed Order, # 3 Certificate of Service)(Halper, Jason) (Entered: Apr. 30, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).356Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) by Glenmark Pharmaceuticals, Inc. USA, Glenmark Pharmaceuticals Ltd. (Attachments: #1 Statement of Material Facts Not in Dispute, # 2 Memorandum of Law In Support of Summary Judgment, # 3 Declaration of George Hykal, # 4 Exhibits A through B to George Hykal Declaration, # 5 Exhibits C through E to George Hykal Declaration, # 6 Exhibits F through H to George Hykal Declaration, # 7 Proposed Order, # 8 Certificate of Service)(Walsh, Liza) Modified on Apr. 12, 2010 (DD, ). (Entered: Jul. 8, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).357Motion to Dismiss for Failure to State a Claim Upon Which Relief May Be Granted and/or for Lack of Subject Matter Jurisdiction by Mylan Inc. (Attachments: #1 Brief in support of Mylan, Inc.'s Motion to Dismiss, # 2 Declaration of Andrew Kozusko in support of Mylan, Inc.'s Motion to Dismiss, # 3 Text of Proposed Order, # 4 Certificate of Service)(Calmann, Arnold) (Entered: Feb. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).358Murphy et al., Some Aspects of the Metabolism and Disposition of Betamethasone, Acta. Endocrinol. 45:498-508 (1964).359Murray-Rust, Intermolecular Interactions of the C-F Bond: The Crystallographic Environment of Fluorinated Carboxylic Acids and Related Structures, J. Am. Chem. Soc. 105:3206-3214 (1993).360Mylan's Opening Claim Construction Brief (Redacted), dated Sep. 30, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).361Nagabhushan, T. L., Kandasamy, D., Tsai, H., Turner, W. N. & Miller, G. H. (1980). Novel class of chloramphenicol analogs with activity against chloramphenicol-resistant and chloramphenicol-susceptible organisms. In Current Chemotherapy and Infectious Disease, vol. 1, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 1979 (Nelson, J. D. & Grassi, C, Eds), pp. 442-443. American Society for Microbiology, Washington, DC.362Napoli et al., 1 α-hydroxy-25-fluorovitamin D3: a potent analogue of 1 α,25-dihydroxyvitamin D3, Biochemistry 17(12):2387-2392 (1978).363Napoli et al., 1-Fluorovitamin D3, a vitamin D3 analogue more active on bone-calcium mobilization than on intestinal-calcium transport, Biochemistry 18(9):1641-1646 (1979).364Negishi et al., Palladium-Catalyzed Acylation of Oganozincs and Other Organometalics as a Convenien Route to Ketones,Tetrahedron Lett. 24(47):5181-5184 (1983).365Nelson et al., Does Ammonia Hydrogen Bond? Science 238(4834): 1670-1674 (1987).366Nikkari et al., The hyperlipidemic hamster as an atherosclerosis model, Artery 18(6)285-290 (1991).367Nobuki et al., Stereoselective syntheses of beta-lactam derivatives by ultrasound promoted Reformatskii reaction, Chemical Abstracts No. 106:17 (1977) Abstract 138174y.368Nobuki et al., Stereoselective syntheses of β-lactam derivatives by ultrasound promoted Reformatskii reaction, Chemical Abstracts No. 106:17 (1977) Abstract 138174y.369Nobuki, O. et al. "Stereoselective syntheses of β-lactam derivatives by ultrasound promoted Reformatskii reaction" Chemical Abstracts No. 106, vol. 17, Apr. 27, 1977 abstract 138174y.370Notice by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA re MOTION for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) of Supplemental Authority in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) (Attachments: # 1 Appendix A)(Lessler, Jay) (Entered: Jan. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).371Notice of Voluntary Dismissal by MSP Singapore Company LLC, Schering Corporation (Attachments: # 1, Attachment Exhibit 1)(Simmerman, Frank) (Entered: Apr. 15, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:09-cv-00167-IMK).372Notice of Voluntary Dismissal by MSP Singapore Company, LLC, Schering Corporation (Attachments: # 1 Exhibit, Exhibit One)(Simmerman, Frank) (Entered: Aug. 19, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:10-cv-99-IMK).373Oguni et al., Stereoselective Synthesis of β-Lactam Derivatives by Ultrasound Promoted Reformatskii Reaction, Chem. Abstracts No. 17, vol. 106:138174y (1987).374Opinion. Signed by Judge Jose L. Linares on Apr. 19, 2010. (jd, ) (Entered: Apr. 19, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).375Opinion. Signed by Judge Jose L. Linares on Sep. 15, 2008. (DD,) (Entered: Sep. 16, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).376Order granting Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue); denying Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting). Signed by Judge Jose L. Linares on Apr. 19, 2010. (jd, ) (Entered: Apr. 19, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).377Order granting Plaintiff's appl. For claims construction.. Signed by Judge Jose L. Linares on Sep. 15, 2008. (DD, ) (Entered: Sep. 16, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).378Order Reinstating re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Glenmark Pharmaceuticals, Inc. USA, Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. Signed by Judge Jose L. Linares on Apr. 9, 2010. (DD, ) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).379Order Vacating re Order granting on Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue), Order on denying Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Apr. 19, 2010 Opinion. Signed by Judge Jose L. Linares on May 10, 2010. (DD, ) (Entered: May 10, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).380Order withdrawing Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue); withdrawing Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting); Signed by Judge Jose L. Linares on Mar. 30, 2010. (DD, ) (Entered: Mar. 31, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).381Ortiz de Montellano, ed., Cytochrome P-450. Structure, Mechanism, and Biochemistry, Ch. 7, Part 3.5, Heteroaton Oxidation and Dealkylation, Plenum Press (1986).382Otto et al., Darstellung und Stereochemie von 3-α-Hydroxybenzyl)-1,4-diphenyl-2-azetidononen, Liebigs Ann. Chem., vol. 1983, issue 7, pp. 1152-1161 (Aug. 15, 1983) (cited as document C16 in the Information Disclosure Statement dated Jul. 7, 2010 in U.S. Appl. No. 12/797,341).383Otto et al., Stereochemistry of dehydration and halogenation of alphaR* and alphaS* isomeric 3-(alpha-hydroyxbenzy1-1-4-dipheny1=2-azetidinones, Chemical Abstracts 19:99 (1983) Abstract 18083h.384Otto et al., Stereochemistry of dehydration and halogenation of αR* and αS* isomeric 3-(α-hydroxybenzyl)-1,4-diphenyl=2-azetidinones, Chemical Abstracts No. 19, vol. 99, Nov. 7, 1983 abstract 158083h.385Otto et al., Stereochemistry of dehydration and halogenation of αR* and αS* isomeric 3-(α-hydroyxbenzy1-1-4-dipheny1=2-azetidinones, Chemical Abstracts 19:99 (1983) Abstract 18083h.386Packard et al., Combined drug therapy for familial hypercholesterolemia, Artery 7(4):281-289 (1980).387Panfil et al., Synthesis of alpha-Lactams from a,alpha-Unsaturated Sugar delta-Lactones, Heterocycles 24:1009-1617(1986).388Panfil et al., Synthesis of α-Lactams from a,α-Unsaturated Sugar δ-Lactones, Heterocycles 24:1009-1617(1986).389Pantil. I. et al., 1986, "Synthesis of β-Lactams from α, β-Unsaturated Sugar δ-Lactones" Heterocycles 34:1609-1617.390Park and Kitteringham, Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications, Drug Metab. Reviews 26(3):605-643 (1994).391Patani and LaVoie, Bioisosterism: A Rational Approach in Drug Design, Chem. Rev. 96(8):3147-3176 (1996).392Peters et al., Biochemistry of Fluoroacetate Poisoning: The Isolation and Some Properties of the Fluoroticarboxylic Acid Inhibitor of Citrate Metabolism, Proc. Roy. Soc. B140:497-507 (1952).393Peters, Some Metabolic Aspects of Fluoroacetate Especially Related to Fluorocitrate, in Carbon Fluorine Compounds: Chemistry, Biochemistry & Biological Activies, A Ciba Foundation Symposium, (Elsevier Excerpta Medica North-Holland), Associated Scientific Publishers, Amsterdam, london, New York, pp. 55-76 (1972).394Physician's Desk Reference, 46th Ed., pp. 1538, 1559-1560 (1992).395Pinedo and Petes, Fluorouracil: Biochemistry and Pharmacology, J. Clin. Oncol. 6(10):1653-1664 (1988).396Plaintiffs' Answer to Impax Laboratories, Inc.'s Counterclaims, dated Oct. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04270 (JLL-CCC)).397Plaintiffs' Answer to Teva Pharmaceuticals USA, Inc.'s Counterclaims, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).398Plaintiffs' Opening Claim Construction Brief, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).399Plaintiffs' Response and Objections to Defendant Mylan Pharmaceuticals Inc.'s First Set of Interrogatories to Plaintiffs (Nos. 1-11), dated Jul. 30, 2010, U.S. District Court for the District of new Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).400Plaintiffs' Responses to Glenmark's Second Set of Interrogatories (Nos. 17-21), dated Sep. 25, 2008, U.S, District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).401Pohl et al., Neoantigens associated with halothane hepatitis, Drug Metab. Rev. 20(2-4):203-217 (1989).402Poston and Foreyt, Scientific and Legal Issues Fenfluramine/Dexfenfluramine Litigation, Tex. Med. 96(2):48-56 (2000).403Pretrial Memorandum by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Dec. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).404R. Mayrhofer et al. 1980. "Simple Preparation of 3-Benzylidene-2-azetilidinones" Synthesis, 247-248.405Ram et al., Potential hypolipidemic agents:Part V†-Synthesis biological activity of new ethyl 4-(2-oxazetidin-4-yl)phenoxyalkanoatest‡, Indian Journal of Chemistry 29B:1134-1137 (1990).406Rebuttal Expert Report of Clayton Heathcock, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).407Rebuttal Expert Report of Jesse David, dated May 8, 2009. U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).408Rebuttal Expert Report of Paul Ortiz de Montellano, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).409Rebuttal Expert Report of Ronald N. Hines, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).410Reg�rdh et al., Plasma Levels and β-Blocking Effect of Hydroxymetoprolol—Metabolite of Metopropol in the Dog, J. Pharm. and Biopharm. 7(5):471-479 (1979) (Abstract only).411Reg�rdh et al., Plasma Levels and β-Blocking Effect of Hydroxymetoprolol—Metabolite of Metopropol in the Dog, J. Pharm. and Biopharm. 7(5)471-479 (1979) (full copy) (cited in abstract from as document C235 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341).412Reifenrath et al., Synthesis and Biological Activity of Fluoroalkylamine Derivatives of Narcotic Analgesics, J. Med. Chem. 23(9):985-990 (1980).413Rekker and Mannhold, Calculation of Drug Lipophilicity—The Hydrophobic Fragmental Constant Approach (Jointly by VCH Verlagsgesellschaft, Weinhehn (Federal Republic of Germany) and VCH Publishers Inc., New York (USA)), Table of Contents (1992).414Reply Affidavit of John D. Sutherland, dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08).415Reply Brief to Opposition to Motion re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) Amended Reply Brief filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Revised Declaration of Jay P. Lessler, # 2 Lttr. to Judge Linares Encl. Amended Reply and Revised Decl.)(Walsh, Liza) (Entered: Aug. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).416Reply Brief to Opposition to Motion re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Resp. To Suppl. Stmn. of Disputed Facts (Redacted), # 2 Decl. of Jay Lessler, # 3 Exhibit A pp. 1-29, # 4 Exhibit A pp. 30-59, # 3 : Exhibit A pp. 60-89, # 6 Exhibit A pp. 90-112, # 7 Exhibit B, # D, Exhibit C)(Walsh, Liza) (Entered: Aug. 10, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).417Reply Brief to Opposition to Motion re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Resp. to Pltffs.' Stmn. of Disputed Facts (Redacted))(Walsh, Liza) (Entered: Aug. 21, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).418Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Arch. Intern. Med. 148:36-69 (1988).419Resnati, Aspects of the Medicinal Chemistry of Fluoroorganic Compounds. Part I, II Farmaco. 45(10):1043-1066 (1990).420Resnati, Aspects of the Medicinal Chemistry of Fluoroorganic Compounds. Part II, II Farmaco. 45(11):1137-1167 (1990).421Rice et al., Fluorine Probes for Investigating the Mechanism of Activation of Indeno[1,2,3-cd] Pyrene to a Tumorigenic Agent, Carcinogenesis 11(11):1971-1974 (1990).422Ridker et al., Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of Rosuvastatin: a prospective study of the JUPITER trial, Lancet 373(9670):1175-82 (2009).423Ridker et al., Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, New Eng. J. Med., 359(21):2195-2207 (2008).424Rietjens and Vervoort, Bioactivation of 4-Fluorinated Anilines to Benzoquinoneimines as Primary Reaction Products, Chem. Biol. Interact. 77(3):263-281 (1991).425Rifai et al., Clinical Chemistry Journal Has Contributed to Progress in Lipid and Lipoprotein Testing for Fifty Years, Clin. Chem. 50:10:1861-1870 (2004).426Roman et al., Renal Tubular Site of Action of Fluoride in Fischer 344 Rats, Anesthesiology 46(4):260-264 (1977).427Rosenblum et al., Discovery of 1-(4- Fluoropheny1)-(3R)43-(4-Fluorophenyl)-(3S)-Hydroxypropylk-(4S)-(4- Hydroxyphenyl)-2-Azetidinone (SCH 58235), A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, J. Med. Chem. 41(6):973-980 (1998).428Rosenblum et al., Discovery of SCH 58235, a potent orally active inhibitor of cholesterol absorption, XII International Symposium on Drugs Affecting Lipid Metabolism, Abstract, p. 61 (1995).429Roth et al., Inhibitors of Acyl-CoA: Cholesterol Acyltransferase. I. Identification and Structure-Activity Relationships of a Novel Series of Fatty Acid Anilide Hypocholesterolemic Agents, J. Med. Chem. 35(9):1609-1617 (1992).430Salisbury et al., Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461, Atherosclerosis 115:45-63 (1995).431Salisbury, B. et al., 1995, "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" Atherosclerosis 115:45-63.432Sandberg and Slaunwhite, Differences in Metabolism of Prednisolone-C14 and Cortisol-C14, J. Clin. Endocrinol. Metab. 17(9):1040-1050 (1957).433Scandinavian Simvastatin Survival Study Group, Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S), Lancet 344(8934):1383-1389 (1994).434Schering Notice of Application for Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Oct. 17, 2008, Federal Court of Canada (Court File No. T-1610-08).435Schnitzer-Polokoff et al., Effects of Acyl-CoA:Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters, Comp. Biochem. Physiol. 99A:665-670 (1991).436Schnitzer-Polokoff, R. et al. 1991, "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma lipoprotein Composition in Hamsters" Comp. Biochem. Physiol. 99A:665-670.437Secrist et al., 2-Fluoroformycin and 2-Aminoformycin, Synthesis and Biological Activity, J. Med. Chem. 28(11):1740-1742 (1985).438Serway, Physics For Scientists & Engineers, Third Edition, (Updated Version), vol. 1, Saunders Golden Sunburst Series (Saunders College Publishing and Harcourt Brace College Publishers, Philadelphia), Table of Contents (1992).439Shankar et al., Synthesis of an Optically Pure 3-Unsubstituted β-Lactam Using an Asymmetric Reformatsky Reaction and its Conversion to Cholesterol Absorption Inhibitors, Tet. Lett. 37(24),4095-4098 (1996).440Shetty and Nelson, Chemical Aspects of Metoprolol Metabolism. Asymmetric Synthesis and Absolute Configuration of the 3-[4-(1-Hydroxy-2-methoxyethyl)phenoxy]-1-(isopropylamino)-2-propanols, the Diastereomeric Benzylic Hydroxylation Metabolites, J. Med. Chem. 31(1):55-59 (1988).441Silverman, Lead Modification: Drug Design and Development, in The Organic Chemistry of Drug Design and Drug Action, 2nd Ed., Sec. 2.2, pp. 29-32 (2004).442Simova, Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline, Chemical Abstracts 15:86 (1977) Abstract 106130h.443Simova, E. "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", Chemical Abstracts No. 15, vol. 86, Apr. 11, 1977, Abstract 106130h.444Sliskovic and White, Therapeutic Potential of ACAT Inhibitors as Lipid Lowering and Anti-Atherosclerotic Agents, Trends Pharmacol. Sci. 12:194-199 (1991).445Sommariva et al., Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia, Int. J. Clin. Pharmacol, Ther. Taxicol., 24(9):505-510 (1986).446St�hle and Ljungdahl-St�hle, Pharmacokinetics and Extracellular Distribution to Blood, Brain, and Muscle of Alovudine (3′-Fluorothymidine) and Zidovudine in the Rat Studied by Microdialysis, J. Acquir. Immune. Defic. Syndr. 6(5):435-439 (1993).447Stary et al., A Definition of Initial, Fatty Streak, and Intermediate Lesions of Atherosclerosis. A Report From the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Arterioscler. Thromb. Vasc. Biol. 14:840-856 (1994).448Statement for the Record in re Deposition of Leslie Z. Benet, Ph.D., dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08).449Statement of Material Fact in Support re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) Resp. to Plaintiffs' Stmnt. of Disputed Material Facts (Confidential) filed by Glenmark Pharmaceuticals Ltd.. (Walsh, Liza) (Entered: Aug. 10, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07- cv-1334 (JLL/ES)).450Statement of Material Fact in Support re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) Resp. to Plaintiffs' Stmnt. of Disputed Material Facts (Confidential) filed by Glenmark Pharmaceuticals Ltd.. (Walsh, Liza) (Entered: Aug. 21, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).451Stedman's Medical Dictionary, www.medilexicon.comimedicaldictionary.php. Lippincott Williams & Wilkins (2006)—"prodrug".452Stein et al., Achieving Lipoprotein Goals in Patients at High Risk with Severe Hypercholesterolemia: Efficacy and Safety of Ezetimibe Co-administered with Atorvastatin. Am Heart J 2004; 148(3),447-55.453Stein et al., Lavastatis alone and in combination with resin in severe primary hypercholesterolemia, Arteriosclerosis 7:513A (1985).454Stein et al., Treatment of severe familial hypercholesterolemia with Lovastatin, resin and niacin, Arteriosclerosis 7:517A (1987).455Steinberg, An interpretive history of the cholesterol controversy: part 1, J. Lipid Res. 45:1583-1593 (1994).456Stipulation and Order dismissing action as to deft. Teva Pharmaceutical Industries, Ltd. Signed by Judge Jose L. Linares on Mar. 31, 2010. (nr) (Entered: Apr. 5, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).457Stipulation and Order terminating Deft. Mylan Inc., etc., Signed by Judge Jose L. Linares on Mar. 16, 2010. (dc, ) (Entered: Mar. 18, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).458Stipulation of Dismissal as to Defendant Mylan Inc. by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Letter)(Halper, Jason) (Entered: Mar. 11, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).459Stipulation of Dismissal as to Defendant Teva Pharmaceutical Industries Ltd. by MSP Singapore Company LLC, Schering Corporation. (Halper, Jason) (Entered: Mar. 30, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)).460Stipulation regarding Teva Pharmaceutical Industries Ltd. And Order, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).461Subcommittee on the National Halothane Study, "Summary of the National Halothane Study" J. Am. Med. Assoc. 197(10):121-134 (1966).462Summary Factfile, May 1992, "Anti-Atherosclerotic Agents" Current Drugs Ltd., pp. A5-A23.463Summary Factile, May 1992, "Anti-Antherosclerotic Agents" Current Drugs Ltd. pp. A5-A23.464Supplemental Expert Report of Ronald G. Brisbois, Ph.D., dated May 22, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).465Sybertz et al., SCH 48461, a novel inhibitor of cholesterol absorption, Atherosclerosis X, Workshop Abstracts, p. 89, Montreal, Oct. 10, 1994.466Sybertz, E. 1995, "SCH 48461, a novel inhibitor of cholesterol absorption" Atherosclerosis pp. 311-315.467Sybertz, E. J., et al., "SCH 48461, a novel inhibitor of cholesterol absorption,"Atherosclerosis X (proceedings of the 10th International Symposium on Atherosclerosis, Montreal, Quebec, Oct. 9-14, 1994), Pub. Elsevier; pp. 311-315, eds. Woodford, F.P. Davington, J. & Sniderman A. (cited as document C24 in the Information Disclosure Statement dated Jul. 7, 2010 in U.S. Appl. No. 12/797,341).468T. Durst et al., 1971, "Metallation of N-Substituted β-Lactams. A Method for the Introduction of 3-Substituents into β-Lactams" Canadian Journal of Chemistry, 50:3196-3201.469Tagg et al., Metabolic studies of tolbutamide in the rat, Biochemical Pharmacology 16(1):143-53 (1967).470Takahashi et al., Crystal structure of the covalent complex formed by a peptidyl-α-α-difluoro-β-keto amide with porcine pancreatic elastase at 1.78Å resolution, J. Am. Chem. Soc. 111:3368-3374 (1989).471Tanaka et al., 26,26,26,27,27,27-Hexafluoro-1,25-Dihydroxyvitarnin D3: A Highly Potent, Long-Lasting Analog of 1,25- Dihydroxyvitamin D3, Arch. Biochem. Biophys. 229(1):348-354 (1984).472Taylor et al., The metabolic fate of prazosin, Xenobiotica 7(6):357-64 (1977).473Taylor, Allen J. et al., Extended Release Niacin or Ezetimibe and Carotid Intima-Media Thickness, New Engl. J. Med. 361(22)2113-2122 (2009).474Teva Pharmaceuticals USA, Inc.'s Answer to Complaint (Attachments: Certification Pursuant to Local Civile Rule 11.2), dated Oct. 7, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)).475Thornber, Isosterism and molecular modification in drug design, Chem. Soc. Review, 18(4),563-580 (1979).476Thummel et al., Human Liver Microsomal Enflurane Defluorination Catalyzed by Cytochrome P-450 2E1 Drug Metab. Dispos. 21:350-357 (1993).477Tidwell, Thomas T., Schiff Bases, and a Century of β-Lactam Synthesis, Angew. Chem. Int. Ed. 47:1016-1020 (2008).478Tingle et al., Influence of Glutathione Conjugation on the Immunogenicity of Dinitrophenyl Derivatives in the Rat, Int. Arch. Allergy Appl. Immunol. 91(2):160-165 (1990).479Tocco et al., Physiological Disposition and Metabolism of 5-(2′,4′ -Difluorophenyl)Salicyclic Acid, a New Salicylate, Drug Metab. Dispos. 3(6):453-466 (1975).480Topliss and Martin, Utilization of Operational Schemes for Analog Synthesis in Drug Design, in Drug Design (Ariens, ed.), ch. 1, pp. 1-21 (1975).481Topliss, Utilization of operational schemes for analog synthesis in drug design, J. Med. Chem. 15(10):1006-1011 (1972).482Transcript of Proceedings held on Aug. 12, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).483Transcript of Proceedings held on Sep. 15, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).484Transcript of Proceedings held on Sep. 8, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)).485Trial Brief Defendants' (Filed Under Seal) by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA. (Attachments: # 1 Certificate of Service)(Lessler, Jay) (Entered: Dec. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)).486Trivedi et al., Inhibitors of Acyl-CoA: Cholesterol Acyltransferase (ACAT). 7. Development of a Series of Substituted N-Phenyl-N-[(1- Phenylcyclopentyl) Methyl]Ureas with Enhanced Hypocholesterolemic Activity, J. Med. Chem. 37(11):1652-1659 (1994).487Tsushima et al., Fluorine-Containing Amino Acids and Their Derivatives, 4. Synthesis and Antibacterial Activity of Threo and Erythro 1-Fluorodehydroxylated Chloramphenicol Analogues, J. Med. Chem. 28(2):253-256 (1985).488U.S. Appl. No. 07/995,488, filed Dec. 12, 1992, Davis.489U.S. Appl. No. 08/102,440, filed Sep. 21, 1993, Rosenblum.490USAN and the USP dictionary of drug names, U.S. Pharmacopeial Convention, Inc., entries ATEVI-ATRIM, p. 62 (though Jun. 15, 1993).491USP Dictionary of USAN and International Drug Names, U.S. Pharmacopeial Convention, Inc., entries AT-101-ATORV, p. 62 (though Jun. 15, 1994).492van Heek et al., Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663, British J. Pharm, 129:1748-1754 (2000).493van Heek et al., Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats, British J. Pharm. 138:1459-1464 (2003).494van Heek et al., In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey through the Identification of the Active Metabolites of SCH4846I, J. Pharm. and Exp. Ther. 283(1):157-163 (1997).495van Heek et al., Isolation and identification of the active metabolite(s) of SCH48461 and possible in vivo mechanism of action for their inhibition of cholesterol absorption, XII Int'l Symp. ON Drugs Affecting Lipid Metabolism, Nov. 7. 1995, Houston, TX.496van Heek et al., The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys, Eur. J. Pharmacol. 415(1):79-84 (2001).497Velican and Velican, Coronary arteries in children up to the age of ten years, II. Intimal thickening and its role in atherosclerotic involvement, Med. Intern, 14:7-24 (1976).498Villines et al., The Arbiter 6-Halts Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration, J. Am. Coll. Cardiol. 55(24)1-6(2010).499Waters et al., Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients with Stable Coronary Disease in the TNT (Treating to New Targets) Study, J. Am Coll Card, 48(9)1793-1799 (2006).500Weeks et al., A Comparison of the Molecular Structures of Six Corticosteroids, J. Am. Chem. Soc. 95(9):2865-2868 (1973).501Weisweiler and Schwandt, Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia, Lancet 1212-1213 (Nov. 22, 1986).502Welch and Eswarakrishnan, Fluorine in Bioorganic Chemistry, John Wiley & Sons, NY, pp. 1-261 (1991).503Welch, Advances in the Preparation of Biologically Active Organofluorine Compounds, Tetrahedron 43(14):3123-3197 (1987).504Wermuth, Chemical modifications of medications with a view to the improvement of their action, Agressologie 7(3):213-219 (1966).505Wilhelm et al., 6-Fluoro-Vitamin D3: A New Antagonist of the Biological Actions of Vitamin D3 and its Metabolites which Interacts with the Intestinal Receptor for 1 α,25(OH)2-Vitamin D3, Arch. Biochem. Biophys. 233(1):127-132 (1984).506Williams, Drug Metabolism, in Principles of Medicinal Chemistry, Third Ed., Ch. 5, pp. 79-117 (Foye, ed.), Lea & Febinger, Philadelphia (1989).507Wirebaugh et al., A Retrospective Review of the Use of Lipid-Lowering Agents in Combination, Specifically, Gemfibrozil and Lovastatin, Pharmacotherapy 12(6):445-450 (1992).508Witztum, Current Approaches to Drug Therapy for the Hypercholesterolemic Patient, Circulation 80:1101-1114 (1989).509Wolff et al., Substrate Specificity of Human Liver Cytochrome P-450 Debrisoquine 4-Hydroxylase Probed Using Immunochemical Inhibition and Chemical Modeling, Cancer Res. 45:2116-2122 (1985).510Wood et al., The Effect of Cimetidine on Anesthetic Metabolism and Toxicity, (1986) Anesth. Analg. 65(5):481488.511Woodrow, Essentials Of Pharmacology For Health Occupations, 4th Ed., Delmar, Thomson Learning, Ch. 7, pp. 87-139—"right amount" (2002).512Written Opinion dated May 16, 1995 in PCT/US94/10099.513Wu et al., A Novel One-Step Diastereo—and Enantioselective Formation of Trans-Azetidinones and its Application to the Total Synthesis of Cholesterol Absorption Inhibitors, J. Org. Chem. 64(10):3714-3718 (1999).514Yumibe et al., Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyoratadine by CYP3A4 and CYP2D6, Biochem. Pharm. 51:165-172 (1996).515Zia-Amirhosseini, Bioactivation by Glucuronide-Conjugate Formation, Adv. Pharma, 27:385-397 (1994).Referenced byCiting PatentFiling datePublication dateApplicantTitleWO2014093189A1Dec 9, 2013Jun 19, 2014Merck Sharp & Dohme Corp.Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitorClassifications U.S. Classification514/210.02, 540/200International ClassificationA61P9/10, A61P3/06, A61K31/395, C07D205/08, A61P7/00, A61K31/35, A61K31/40, A61K31/21, A61K31/397Cooperative ClassificationC07D205/08European ClassificationC07D205/08Legal EventsDateCodeEventDescriptionSep 14, 2012ASAssignmentOwner name: MERCK SHARP & DOHME CORP., NEW JERSEYFree format text: CHANGE OF NAME;ASSIGNOR:SCHERING CORPORATION;REEL/FRAME:028974/0213Effective date: 20120502Owner name: SCHERING CORPORATION, NEW JERSEYFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSENBLUM, STUART B.;DUGAR, SUNDEEP;BURNETT, DUANE A.;AND OTHERS;REEL/FRAME:028974/0188Effective date: 19940803RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services